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1.1 What is epilepsy? 
 
Epilepsy is one of the most common disorders of the brain with around 50 million people 
affected world-wide (World Health Organization 2012). The term “epilepsy” comprises a 
heterogeneous spectrum of neurological conditions characterized by unprovoked, recurrent 
seizures due to abnormal, synchronized activity of central neurons. In addition to irregular 
neuronal firing, important elements to define a seizure are its transient occurrence and its 
clinical manifestation (Fisher et al. 2005) with the latter ranging from imperceptible absences 
to generalized tonic-clonic jerks and from relatively benign to severe and life-threatening. The 
burden of epilepsy, however, extends beyond the effects of seizures themselves: Many 
patients have to contend with associated cognitive, psychological, behavioral and social 
problems markedly impairing quality of life (Kerr 2012). Furthermore, affected individuals 
and their families may have to deal with the increased risk of accidental injury and even 
premature death (Fazel et al. 2013). 
 
Different schemes have been developed to classify the epilepsies. The classification by 
etiology is one of the most commonly used concepts and roughly distinguishes three groups: 
epilepsy with a genetic basis often referred to as idiopathic or genetic epilepsy, epilepsy due 
to structural changes in the brain also called symptomatic or structural-metabolic epilepsy and 
simply epilepsy of unknown etiology (Berg et al. 2010). In reality, the boundaries between the 
different etiological groups are much more blurred than in this classification. It has become 
increasingly clear that many epilepsies follow a complex pattern of inheritance where both, 
genetic and acquired factors, contribute to the epilepsy phenotype (Berkovic et al. 2006). 
However, the different epilepsy syndromes tend toward one or the other end of the etiological 
spectrum between genetic and symptomatic. 
In Europe, symptomatic epilepsies only account for about one third of all epilepsies while two 
thirds have a genetic basis or no obvious identifiable cause (Banerjee et al. 2009). 
Epilepsies with a strong genetic background often have their onset in childhood or youth. 






1.2 Febrile seizures and fever-associated epilepsies 
 
Febrile seizures (FS) are the most common convulsive event in childhood. They affect about 
3% of all children (Nelson and Ellenberg 1978; Ross et al. 1980; Verity et al. 1985) and 
generally occur as a benign, self-limiting event between the age of 6 months and 6 years. FS 
are predominantly brief, generalized tonic-clonic seizures (GTCS) precipitated by fever as 
present during common childhood infections that do not affect the CNS (Baulac et al. 2004). 
Thus, FS have a clear provoking factor and are not traditionally diagnosed as epilepsy. 
However, FS might be a manifestation of less frequent fever-associated epilepsy syndromes 
like febrile seizures plus (FS+), genetic epilepsies with febrile seizures plus (GEFS+) and 
Dravet syndrome, first described as severe myoclonic epilepsy of infancy (SMEI). 
The syndrome of FS+ includes different clinical presentations. One scenario involves FS 
lasting beyond the age of 6 years. A second type of presentation of FS+ is the occurrence of 
FS with additional afebrile seizures. The latter may coexist with FS during the typical time 
frame of 6 months to 6 years, but can also occur after remittance of FS (Scheffer and 
Berkovic 1997; Scheffer et al. 2005). 
FS and FS+ represent the most common phenotypes of the familial epilepsy syndrome 
GEFS+. The term was introduced to describe families in which FS and epilepsy coexist 
(Scheffer and Berkovic 1997). Different FS-related phenotypes may segregate within one 
family, a diagnosis of GEFS+ requiring at least two affected family members (Scheffer et al. 
2009). The phenotypic spectrum of GEFS+ shows a high degree of diversity as it ranges from 
classical FS and FS+ with or without additional afebrile tonic-clonic, myoclonic, atonic or 
absence seizures to the rare and severe Dravet syndrome. 
Dravet syndrome is an epileptic encephalopathy, i.e. an epilepsy syndrome where seizures 
lead to impaired brain function and cognitive decline (Engel 2001). Dravet syndrome usually 
starts in healthy infants during the first year of life with FS often presenting as hemiclonic or 
generalized febrile status epilepticus (Dravet 2011). These seizures may recur during the 
following months with hemiclonic seizures changing to the alternate side. Later on, between 
one and four years, other seizure types develop including myoclonic seizures, focal 
(dyscognitive) seizures and atypical absence seizures (Scheffer et al. 2009). Another common 
feature of patients with Dravet syndrome is the temperature sensitivity with fever and warm 
baths triggering seizures. With advancing age, Dravet syndrome shows a devastating course 
with ongoing seizures, developmental slowing, cognitive regression and additional 
neurological symptoms, such as ataxia and pyramidal signs (Dravet 2011). 
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Some patients show a clinical picture similar to Dravet syndrome but with atypical features. 
One epilepsy syndrome very close to Dravet syndrome is severe idiopathic generalized 
epilepsy of infancy (SIGEI), where the major distinguishing feature is that GTCS represent 
the predominant seizure type while myoclonic seizures are absent or subtle (Doose et al. 
1998). In literature, the syndrome of SIGEI also appears under the name of intractable 
childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) (Fujiwara et al. 2003). 
 
1.3 Genetic contribution to the epilepsies 
 
1.3.1 Genetic contribution to the epilepsies in general 
 
Since antiquity, genetics have been recognized as an important etiologic factor of epilepsy 
(Magiorkinis et al. 2010). Whereas the early idea of epilepsy as a genetic disorder was based 
on simple observations, in the mid-20
th
 century, twin studies emerged as a first scientific 
approach to investigate the importance of genetic factors for epilepsy. Up to today, many twin 
studies provided evidence of a genetic contribution to the disease by showing that the 
concordance rates for disease occurrence in monozygotic twins considerably exceed those in 
dizygotic twins (Lennox 1951; Berkovic et al. 1998; Miller et al. 1999; Kjeldsen et al. 2001; 
Corey et al. 2011). 
Family studies are another efficient tool to demonstrate the influence of genetics on the 
etiology of epilepsy. Comparing the prevalence of epilepsy in family members of affected 
individuals to the prevalence in the general population, family studies revealed that offspring 
of epileptic parents are at twice to fivefold the risk to develop epilepsy (Winawer and Shinnar 
2005). Higher prevalence of epilepsy among first-degree relatives of probands with idiopathic 
than with symptomatic epilepsy (Bianchi et al. 2003; Wakamoto et al. 2004) supports the 
general view that genetic factors are particularly important for idiopathic epilepsies. 
 
1.3.2 Genetic contribution to febrile seizures and fever-associated epilepsies 
 
As well as for epilepsy in general, twin and family studies demonstrated a strong genetic 
contribution to FS and fever-associated epilepsies. Several studies investigated twins with FS 
revealing significantly higher probandwise concordance rates for monozygotic twins ranging 
from 0.36 to 0.42 than for dizygotic twins ranging from 0.12 to 0.14 (Miller et al. 1999; 
Kjeldsen et al. 2002; Corey et al. 2011). Family studies showed that relatives of affected have 
a higher risk of FS compared with the general population (Winawer and Shinnar 2005). 
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Furthermore, a recent twin study confirmed the genetic contribution to FS+ and FS with later 
epilepsy with casewise concordance rates for monozygotic to dizygotic twins of 0.83 to 0.22 
and 0.25 to 0.0 respectively (Eckhaus et al. 2013). 
 
1.4 Results of epilepsy research 
 
1.4.1 Genetics of epilepsy – an overview 
 
20 years ago, the first epilepsy gene CHRNA4 was reported in a large Australian family with 
autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) (Steinlein et al. 1995). The 
identification of CHRNA4 coding for the α4 subunit of the nicotinic acetylcholine receptor, a 
ligand-gated ion channel, was soon followed by the discovery of further ion channel genes: 
Causative variants were identified in subunits of potassium channels (KCNQ2 and KCNQ3) 
(Biervert et al. 1998; Charlier et al. 1998; Singh et al. 1998; Hirose et al. 2000), sodium 
channels (SCN1B, SCN1A, SCN2A) (Wallace et al. 1998; Escayg et al. 2000; Claes et al. 
2001; Sugawara et al. 2001; Wallace et al. 2001b; Heron et al. 2002), gamma-aminobutyric 
acid receptors (GABRG2, GABRA1) (Baulac et al. 2001; Wallace et al. 2001a; Cossette et al. 
2002; Maljevic et al. 2006) and additional subunits of nicotinic acetylcholine receptors 
(CHRNB2, CHRNA2) (De Fusco et al. 2000; Aridon et al. 2006) leading to the channelopathy 
concept for the pathogenesis of idiopathic epilepsies. However, in 2002, pedigrees of 
individuals with autosomal dominant temporal lobe epilepsy (ADTLE) revealed mutations in 
the first non-ion channel gene LGI1 (Kalachikov et al. 2002) involved in the regulation of 
synaptic transmission (Fukata et al. 2006). 
 
So far, gene discovery has especially been successful in monogenic familial epilepsies and 
sporadic epileptic encephalopathies. Targeted approaches like linkage analysis in large 
families and subsequent candidate gene sequencing as performed in ADNFLE (Phillips et al. 
1995; Steinlein et al. 1995) and ADTLE (Ottman et al. 1995; Kalachikov et al. 2002) led to 
the detection of causative genes. New massive parallel sequencing techniques enable the 
screening of multiple genes, the exome or even the whole genome in many patients at once 
and thus simplify the search for causative variants. Using these high-throughput sequencing 
methods, long-sought genes for familial epilepsies and causative mutations for sporadic 
epileptic encephalopathies have been identified. In 2012, PRRT2 was reported as the major 
gene for benign familial infantile seizures (BFIS) (Heron et al. 2012a; Schubert et al. 2012) 
after exome sequencing had detected the gene in paroxysmal kinesigenic dyskinesia (PKD), a 
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movement disorder also occurring in BFIS families (Chen et al. 2011). Exome sequencing 
revealed KCNT1 mutations in 6/12 patients with malignant migrating partial seizures of 
infancy (MMPSI) (Barcia et al. 2012) and causative KCNT1 variants were also found in 
severe ADNFLE (Heron et al. 2012b). 
 
De novo mutations in different genes have been discovered as a major cause of epileptic 
encephalopathies explaining at least 12% of cases (EuroEPINOMICS-RES Consortium et al. 
2014). To only name some, de novo variants in SCN1A, STXBP1 and CDKL5 were reported in 
early infantile epileptic encephalopathies (Nicita et al. 2012). Recent studies extended the 
phenotypic spectrum of known epilepsy genes, but also discovered new genes for epileptic 
encephalopathies: Mutations in GRIN2A were detected in patients with severe rolandic 
epilepsy and epilepsy-aphasia syndromes (Carvill et al. 2013b; Lemke et al. 2013) and CHD2 
was found to cause a fever-sensitive myoclonic encephalopathy with similarities to Dravet 
syndrome (Suls et al. 2013b). As LGI1 and other epilepsy genes, CHD2 and PRRT2 are not 
encoding ion channel proteins further contesting the channelopathy concept. 
Apart from sequence mutations, rare deletions and duplications contribute to the genetic basis 
of epileptic encephalopathies and were reported in 7.9% of patients (Mefford et al. 2011). 
 
Regarding the overall burden of epilepsy monogenic familial epilepsies and epileptic 
encephalopathies are rare syndromes. In common epilepsies like the genetic generalized 
epilepsies (GGEs) accounting for 15-20% of all epilepsy syndromes (Jallon and Latour 2005), 
the discovery of underlying genetic variation has only just begun. GGEs are presumed to 
follow a complex inheritance pattern (Ottman 2005) and mutations with a strong pathogenic 
effect were only discovered in rare familial forms of these disorders (Lachance-Touchette et 
al. 2011). CACNA1H and GABRD were discussed as susceptibility genes contributing to the 
pathogenesis of GGE (Chen et al. 2003; Dibbens et al. 2004). Important progress in the 
identification of variants predisposing to GGE was made by investigating structural variation: 
Recurrent microdeletions at 15q13.3, 15q11.2 and 16p13.11 were identified as important risk 
factors for GGE occurring in three percent of patients (Helbig et al. 2009; de Kovel et al. 
2010). 
Another disorder that might present with a GGE phenotype is the GLUT1 deficiency 
syndrome encompassing a broad phenotypic spectrum with epileptic encephalopathies at the 
severe end (De Vivo et al. 1991; De Giorgis and Veggiotti 2013). In these patients, SLC2A1 
mutations lead to an impaired glucose transport over the blood-brain barrier (Seidner et al. 
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1998). Ketogenic diet is a treatment for GLUT1 deficiency and may improve seizure and 
cognitive outcome. 
 
1.4.2 Genetics of febrile seizures and fever-associated epilepsies 
 
Although the majority of FS is assumed to have polygenic inheritance (Rich et al. 1987), the 
examination of monogenic FS and fever-associated epilepsies has been the most successful 
approach towards gene discovery in these disorders. Investigating a large pedigree of family 
members with generalized epilepsies with a predominance of FS, Scheffer and Berkovic 
developed the concept of GEFS+ as a familial syndrome and diagnostic entity (Scheffer and 
Berkovic 1997). The use of this concept in subsequent genetic studies revealed the four genes 
SCN1A, SCN1B, SCN2A and GABRG2 (table 1). 
SCN1B was identified in a large GEFS+ pedigree (Wallace et al. 1998) and Escayg and 
colleagues discovered SCN1A mutations in two families with GEFS+ (Escayg et al. 2000). 
Later on, the combined frequency of SCN1B and SCN1A mutations in GEFS+ families was 
found to be 17% (Wallace et al. 2001b). Due to phenotypic overlaps and patients with Dravet 
syndrome and a family history of seizures, Dravet syndrome was added to the severe end of 
the GEFS+ spectrum (Singh et al. 2001). Claes and colleagues then sequenced SCN1A in 
Dravet syndrome and identified de novo mutations in all seven patients investigated (Claes et 
al. 2001). Subsequent studies confirmed SCN1A as the major causative gene of Dravet 
syndrome (Sugawara et al. 2002; Claes et al. 2003) with more than 70% of patients carrying a 
mutation (Marini et al. 2011). SCN1A mutations were also, but less frequently found in 
patients with SIGEI (Ebach et al. 2005). SCN2A has been implicated in a patient with FS+ and 
his father with FS (Sugawara et al. 2001). In addition, SCN2A plays a role in early infantile 
epileptic encephalopathies including Dravet syndrome (Shi et al. 2012). GABRG2 was 
reported in GEFS+ pedigrees including a patient with Dravet syndrome (Baulac et al. 2001; 
Harkin et al. 2002), a family with childhood absence epilepsy (CAE) and FS (Wallace et al. 
2001a) and in familial FS (Audenaert et al. 2006). 
Only recently, STX1B mutations were identified in a family with fever-associated epilepsies 
consistent with the GEFS+ spectrum (Schubert et al. 2014) emphasizing the relevance of this 
concept. 
The search for de novo mutations has been the most important approach for gene discovery in 
Dravet syndrome. It not only revealed the importance of SCN1A, but also identified variants 
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in CHD2 (Suls et al. 2013b). Furthermore, mutations in PCDH19 were reported in female 
individuals with a Dravet-like phenotype (Depienne et al. 2009). 
Deletions and duplication of SCN1A in 2-3% of patients with Dravet syndrome (Marini et al. 
2009) and 17q12 duplications in 0.45% (1/222) of individuals with familial FS and GEFS+ 
(Hardies et al. 2013) suggest that structural variation also contributes to the genetic 
background of fever-associated epilepsies.  
 
Gene Protein Function 
SCN1A voltage-gated sodium channel type I, 
alpha subunit 
ion channel subunit (Oliva et al. 2012) 
SCN1B voltage-gated sodium channel type I, 
beta subunit 
ion channel subunit (Oliva et al. 2012) 
SCN2A voltage-gated sodium channel type II, 
alpha subunit 
ion channel subunit (Oliva et al. 2012) 
GABRG2 gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 subunit 
ion channel subunit (Macdonald et al. 2010) 
STX1B syntaxin 1B involved in the release of presynaptic vesicles 
(Mishima et al. 2014) 
CHD2 chromodomain helicase DNA binding 
protein 2 
involved in modification of chromatin structure 
(Marfella and Imbalzano 2007) 
PCDH19 protocadherin 19 involved in cell-adhesion (Emond et al. 2011) 
Table 1. Genes involved in fever-associated epilepsies. 
 
1.5 Targeted resequencing 
 
DNA sequencing is used to detect single nucleotide variants (SNVs) and small insertions and 
deletions (indels). What began with non-automated Sanger sequencing has since advanced to 
today’s high-throughput sequencing technologies also known as massive parallel sequencing 
or “next-generation” sequencing. The new techniques have revolutionized the field owing to 
their time-efficiency and cost-effectiveness, greatly accelerating disease gene discovery (see 
examples in chapter 1.4.1). Despite these advances, it is not yet broadly affordable to perform 
whole-exome or whole-genome sequencing for large numbers of patients. Instead, alternative 
approaches are taken to interrogate only certain intervals of the genome, for example several 
genes, a technique also known as targeted resequencing.  
Different studies have shown that targeted resequencing can be a useful diagnostic tool in 
epilepsy. Lemke et al. performed gene panel sequencing in patients with various epilepsies 
and identified disease-causing variants in 16 of 33 individuals (Lemke et al. 2012). Another 
gene panel approach was applied to 500 patients with epileptic encephalopathies: Targeted 




As epileptic disorders are genetically heterogeneous it is difficult to choose only one 
candidate gene for sequencing. Gene panels strike a balance between single gene and whole-
exome or whole-genome sequencing and are already commercially available for genetic 
testing in epilepsy. 
 
1.6 Copy number variation analysis 
 
Copy number variants (CNVs) are deletions and duplications ranging from 1kb to a few Mb 
in size (Feuk et al. 2006). About one decade ago, these submicroscopic changes have been 
identified as a major source of genomic structural variation covering 12% of the human 
genome (Iafrate et al. 2004; Sebat et al. 2004; Redon et al. 2006). CNVs can be divided in two 
categories: recurrent and non-recurrent. Recurrent CNVs arise by non-allelic homologous 
recombination (NAHR). Regions of high sequence similarity lead to a misalignment of 
homologous chromosomes during meiosis so that subsequent rearrangements result in 
deletions and duplications (Watson et al. 2014). While recurrent CNVs occur at the same 
position in unrelated individuals, non-recurrent CNVs occur throughout the genome without 
consistent breakpoints. 
 
CNVs may contribute to normal phenotypic variation, but have also been connected to 
disease. Charcot-Marie-Tooth type IA, Prader-Willi, Angelman and Williams-Beuren 
syndrome are neurological or neurodevelopmental disorders associated with recurrent CNVs 
(Butler et al. 1986; Magenis et al. 1987; Lupski et al. 1991; Perez Jurado et al. 1996). Patients 
with intellectual disability (ID), autism and schizophrenia constituted the first large disease 
cohorts systematically studied for CNVs (Sebat et al. 2007; International Schizophrenia 
Consortium 2008; Marshall et al. 2008; Sagoo et al. 2009). As the phenotypic spectrum of 
rare recurrent CNVs identified in these disorders were overlapping and also included seizures, 
epilepsy cohorts were subsequently investigated for copy number changes. Genome-wide 
CNV screening in GGE identified rare CNVs in 8.9% of patients including recurrent 
microdeletions at 15q11.2, 15q13.3 and 16p13.11 in 3% of individuals (Mefford et al. 2010). 
With an odds ratio of 68, the microdeletion 15q13.3 is the most important risk factor for GGE 
identified today (Dibbens et al. 2009). Heinzen and colleagues investigated more than 3000 
patients with focal epilepsies and also found a significant enrichment of 16p13.11 deletions 
compared to controls. Interestingly, 15q13.3 deletions seem to represent a risk factor 
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specifically for generalized epilepsies as recurrent CNVs at this locus were not identified in 
focal forms (Heinzen et al. 2010). 
7.9% of patients with epileptic encephalopathies carry rare CNVs. Microdeletions at 15q11.2, 
15q13.3 and 16p13.11 were not identified in these individuals indicating a different genetic 
architecture for these severe epilepsies (Mefford et al. 2011). 
 
CNVs may also highlight novel epilepsy genes. For example, a deletion encompassing 
PCDH19 was identified in a patient with Dravet syndrome. Subsequent sequencing of 
PCDH19 in additional individuals revealed sequence mutations and established PCDH19 as 
an epilepsy gene (Depienne et al. 2009). Carvill et al. located CHD2 in the smallest region of 
overlap of non-recurrent 15q26 deletions and identified de novo mutations of the gene in 





FS and fever-associated epilepsy syndromes considerably contribute to the burden of 
epilepsy. Their etiology involves a strong genetic component and several genes for 
monogenic FS and fever-associated epilepsies have been identified. However, most patients 
do not carry mutations in these genes. Many cases remain unexplained and further genetic 
variants contributing to these genetically heterogeneous disorders need to be identified. 
Targeted resequencing was successfully performed in different epilepsies. Most pathogenic 
mutations found in FS and fever-associated epilepsies were SNVs, but the identification of 
CNVs in GGE and epileptic encephalopathies suggests that deletions and duplications might 
also be involved in the pathogenesis of these epilepsies. 
 
We performed targeted resequencing and a genome-wide CNV screening in patients with 
recurrent FS and fever-associated epilepsies to  
 
1) evaluate the impact of 19 candidate epilepsy genes in recurrent FS and fever-associated 
epilepsies and define the phenotypic spectrum of 13 known epilepsy genes. 
 




2 Patients and Methods 
 
2.1 Patient cohort selection 
 
The ethics committee of the Christian-Albrechts-University Kiel, the Antwerp University 
Hospital and the University of Washington, Seattle approved this study. 
86 patients with fever-associated epilepsies were selected from the biobanks of the 
Department of Neuropediatrics at the Christian-Albrechts-University Kiel and the Vlaams 
Instituut voor Biotechnologie (VIB) Department of Molecular Genetics at the University of 
Antwerp. 
DNA was obtained from blood lymphocytes or derived from whole genome amplification 
(WGA) following standard protocols. 
 
Two cohorts of patients were investigated. In cohort 1 targeted resequencing of candidate and 
known epilepsy genes was performed to detect novel causative mutations within these genes. 
In cohort 2 genome-wide array comparative genomic hybridization (array CGH) was 
performed to detect pathogenic CNVs. 
 
2.1.1 Cohort 1: Targeted resequencing 
 
Cohort 1 consisted of 84 patients with fever-related seizures or status epilepticus in the first 
years of life as the most prominent clinical features (table 2). Two additional individuals 
carrying SCN1A mutations were included as positive controls. 35/43 individuals with typical 
or atypical Dravet syndrome previously tested negative for SCN1A sequence mutations. 
 
Epilepsy phenotype Number of patients (% of total cohort) 
Dravet syndrome 43 (51%) 
       typical Dravet syndrome 22 
       atypical Dravet syndrome/SIGEI 21 
GEFS+/FS+ 27 (32%) 
       FS+ afebrile 15 
       FS+ prolonged 7 
       FS+ absence 2 
       FS+ other 3 
recurrent FS (≥4) 11 (13%) 
unclassified fever-associated epilepsy 3 (4%) 
Total 84 
Table 2. Patient phenotypes for cohort 1. FS, febrile seizures; FS+, febrile seizures plus; GEFS+, 




Classification was performed similarly as described in Hartmann et al. 2015: Most patients 
with atypical Dravet syndrome were classified as having severe idiopathic generalized 
epilepsy of infancy (SIGEI) (Doose et al. 1998) with predominant GTCS and without or with 
only subtle myoclonic seizures. Furthermore, patients with SIGEI were lacking the alternating 
hemiclonic seizures of typical Dravet syndrome. 
All patients with GEFS+/FS+ presented with simple FS with additional seizure types or FS 
persisting beyond the usual age of remission. Patients with additional afebrile GTCS were 
classified as “FS+ afebrile”. Individuals with FS persisting beyond the age of six years were 
categorized as “FS+ prolonged”. If additional absence seizures occurred, the phenotype was 
referred to as “FS+ absence”. Three patients had additional myoclonic, astatic, atonic and 
tonic seizures and constituted the group of “FS+ other”. 
Patients with recurrent FS were included if they had at least four FS. 
Subjects with unclassified fever-associated epilepsy had prominent fever-associated seizures 
and additional syndromic features including profound ID, autism, short stature, dysmorphic 
features, macrocephaly and muscular hypotonia. In these patients, a diagnosis of FS+, Dravet 
syndrome or SIGEI would be justifiable if only regarding their epilepsy. 
 
2.1.2 Cohort 2: Copy number variation analysis 
 
Cohort 2 constituted a subgroup of cohort 1 and consisted of 36 patients with typical and 
atypical Dravet syndrome (SIGEI), GEFS+/FS+ and unclassified fever-associated epilepsy 
(table 3). 
All individuals tested negative for SCN1A sequence mutations as part of the investigations in 
cohort 1 and 18/36 patients had a negative screening for SCN1A deletions and duplications 
using multiplex ligation-dependent probe amplification (MLPA) or multiplex amplicon 
quantification (MAQ). The remaining patients were not previously investigated for copy 
number changes of SCN1A. 
Among all patients, a diagnosis of ID was present in 26/36 (72%) patients, autism was 
diagnosed in 5/36 (14%) individuals and 6/36 (17%) patients had congenital anomalies 
(CGA). 18/26 (69%) of the patients with ID had normal development before seizure onset and 
cognitive impairment started with epileptic activity in terms of an epileptic encephalopathy 








Number of patients with 
ID with onset 








2 18 3 4 4 
       typical Dravet 
       syndrome 
13 
       atypical Dravet 
       syndrome/SIGEI 
10 
GEFS+/FS+ 11 (31%) 
1
a
 0 0 0 0 
       FS+ afebrile 4 
       FS+ prolonged 4 
       FS+ absence 1 
       FS+ other 2 
unclassified fever-
associated epilepsy 












Table 3. Patient phenotypes for cohort 2. 
CGA, congenital anomalies; FS+, febrile seizures plus; GEFS+, genetic epilepsy with febrile seizures 
plus; ID, intellectual disability; SIGEI, severe idiopathic generalized epilepsy of infancy. 
a
 patient with borderline ID (full scale intelligence quotient of 75 in the Hamburg Wechsler 
Intelligenztest für Kinder IV as the German adaption of Wechsler Intelligence Scale for Children IV) 
(Daseking et al. 2007); (table as published in Hartmann et al 2015, license agreement with John Wiley 
and Sons available) 
 
2.2 Targeted resequencing 
 
Targeted resequencing was performed in 19 candidate 
and 13 known epilepsy genes in order to identify 
mutations in cohort 1 (table 4). 
 
2.2.1 Selecting genes for targeted resequencing 
 
Dr. Gemma Carvill (Postdoctoral fellow, Department of 
Pediatrics, Division of Genetic Medicine, University of 
Washington, Seattle) selected 32 candidate and known 
epilepsy genes for targeted resequencing. 
13 known epilepsy genes were selected based on the 
presence of mutations in more than one individual and 
are generally associated with more severe presentations. 
Candidate epilepsy genes were selected from within 
epilepsy-associated CNVs from published studies 
























(Heinzen et al. 2010; Mefford et al. 2010; Mefford et al. 2011) and unpublished data as 
described in Carvill et al. 2013 (Supplementary Note and Supplementary Table 2). 
 
2.2.2 Capture methods for targeted resequencing: molecular inversion probes 
 
Targeted resequencing allows the selective interrogation of specific regions of the genome. To 
capture all regions of interest several methods have been developed including multiplex 
polymerase chain reaction (PCR), capture-by-circularization and capture-by-hybridization 
methods (Turner et al. 2009b). In this study, we used molecular inversion probes (MIPs), that 
fall into the category of capture-by-circularization, to capture and amplify all exons and 
intron-exon-boundaries of the 32 candidate and known epilepsy genes (table 4) for subsequent 
next-generation sequencing in all individuals of cohort 1. Advantages of MIP capture 
methods are the high specificity, good scalability and the compatibility with a high level of 
multiplexing. 
MIPs are single stranded DNA molecules consisting of two target-specific arms connected by 
a common backbone. The name “molecular inversion probe” is derived from the 
configurational inversion of the whole molecule upon target binding. 
MIPs originate from padlock probes that were initially used to specifically detect single 
nucleotide changes (Nilsson et al. 1994; Hardenbol et al. 2003). 
In contrast to padlock probes, the targeting arms of MIPs are 112bp apart when hybridized to 
their target, and by performing a “gap fill” step the target sequence of the patient can be 
captured for future sequencing. The process of MIP capture is shown in figure 1. Briefly, 
patient DNA was denatured and MIPs were allowed to hybridize to target DNA. DNA 
polymerase was then used to fill the gap with target-complementary sequence and enzymatic 
ligation created a single circular MIP molecule. Exonuclease treatment removed remaining 
linear DNA molecules from the reaction mix. The MIP regions containing the target’s 
complement were amplified in a multitemplate PCR using universal primers that bound in the 
common backbone. The primers were connected to unique 8bp barcodes and universal 
sequencing adaptors that were hence introduced into each PCR product so that these could be 
pooled together. Subsequent bead purification of PCR products resulted in a target-enriched 




Figure 1. Target capture using MIPs. 
MIPs consist of target-specific arms (yellow) 
and a common backbone (green) containing 
universal binding sites for PCR primers. MIPs 
hybridize to their target DNA and undergo 
configurational inversion. An extension and 
ligation step results in circularized MIPs 
carrying a copy of the target. Captured 
sequences are amplified in a multitemplate PCR 
incorporating sequencing adaptors (black) and 
unique 8bp barcodes. Purified PCR products are 
directly sequenced producing paired-end reads. 
(figure as published in Turner et al. 2009a, 









In order to capture the 32 candidate and known epilepsy genes, a total target size of 90,071bp, 
1325 MIPs with a length of 70bp and a gap-size of 112bp were designed as previously 
described (O'Roak et al. 2012, Supplementary Material, p. 4) (for MIP sequences see annex, 
table S1). Integrated DNA Technologies (Coralville, IA) performed column synthesis of 
MIPs. 
 
2.2.3 Pooling of MIPs 
 
In order to multiplex capture reactions, all 1325 MIPs with a concentration of 100μmol/l were 
pooled together. In previous experiments using the same probes, uniformity calculations 
revealed 147 MIPs with a coverage below 100X. These poorly capturing MIPs were therefore 
added at a 50 times higher amount than the remaining MIPs to the final pool. 
 
2.2.4 Phosphorylation of MIPs 
 
MIPs have to be 5’-phosphorylated so that the DNA sequence in the gap fill can be ligated to 
the ligation arm allowing the molecule to circularize. This kinase reaction was performed in 





Reagent Amount in μl Company 
pooled MIPs 37.5 Integrated DNA Technologies (Coralville, IA) 
10X T4 DNA Ligase Reaction 
Buffer 
5 New England BioLabs (Ipswich, MA) 
T4 Polynucleotide Kinase 
(3' phosphatase minus) 
2.5 New England BioLabs (Ipswich, MA) 
Molecular Biology Grade Water 5 Mediatech (Manassas, VA) 
Table 5. Reagents for phosphorylation. 
 
Reaction conditions were set on the GeneAmp PCR System 9700 (Applied Biosystems, 
Carlsbad, CA) as follows: 
 
incubation:   37°C for 45 min 
kinase heat inactivation: 65°C for 20 min 
cooling:   4°C until program was stopped 
 
2.2.5 Target capture 
 
For target capture the MIPs’ ligation and extension arms were hybridized to the denatured 
proband DNA. The gap was filled by DNA polymerase using free nucleotides. Finally, ligase 
connected the gap-fill with the ligation arm resulting in a circularized molecule. The reaction 
was also performed for a non-template control (NTC) where DNA was replaced by water. 
Table 6 shows all reagents of the reaction mix. 
 
Reagent Amount in μl Company 
Ampligase 10X Reaction Buffer 2.5 Epicentre (Madison, WI) 
pooled, phosphorylated MIPs, 
diluted 1:250 
0.3113 Integrated DNA Technologies 
(Coralville, IA) 
dNTP mix, 25mM each, diluted 1:100 0.0640 Fermentas (Waltham, MA) 
AmpliTaq DNA Polymerase, Stoffel 
Fragment 10U/μl 
0.04 Applied Biosystems (Carlsbad, CA) 
Ampligase DNA Ligase 100U/μl  0.01 Epicentre (Madison, WI) 
Molecular Biology Grade Water 17.0747 Mediatech (Manassas, VA) 
Table 6. Reagents for target capture. 
 
For each sample 5μl of DNA with c = 20ng/μl were added to 20μl of reaction mix. 
 
Reaction conditions were set on the GeneAmp PCR System 9700 (Applied Biosystems, 





denaturation:  95°C for 10min 
capture:  65°C for 24h 
cooling:  4°C until program was stopped 
 
2.2.6 Exonuclease treatment 
 
The capture product was treated with exonucleases I and III to remove uncircularized 
molecules and any remaining linear DNA. 2μl of the following reaction mix (table 7) were 
added to 25μl of each target capture product. 
 
Reagent Amount in μl Company 
Exonuclease 1 
(E. coli), 20000U/ml 
0.5 New England Bio Labs (Ipswich, MA) 
Exonuclease 3 
(E. coli), 100000U/ml 
0.5 New England Bio Labs (Ipswich, MA) 
Ampligase 10X Reaction Buffer 0.2 Epicentre (Madison, WI) 
Molecular Biology Grade Water 0.8 Mediatech (Manassas, VA) 
Table 7. Reagents for exonuclease treatment. 
 
Reaction conditions were set on the GeneAmp PCR System 9700 (Applied Biosystems, 
Carlsbad, CA) as follows: 
 
incubation:   37°C for 30min 
enzyme inactivation:  95°C for 5min 
cooling:   4°C until program was stopped 
 
2.2.7 Real time PCR 
 
Real time PCR (RT-PCR) was performed for a subset of 17 exonuclease-treated capture 
reactions in order to qualitatively validate capture efficiency. Additionally, the number of 
PCR cycles required for effective target amplification of all samples was estimated. The 
investigated reactions included products from eight DNA samples, eight WGA samples and 
the NTC. 
SYBR green (Invitrogen, Carlsbad, CA), a fluorescent dye that intercalates into double-
stranded DNA, was used to track target amplification, as the accumulation of RT-PCR 
products correlates with the increase in fluorescence intensity at the end of every cycle. The 
fluorescence intensity was measured for each single reaction by a laser-detector-system. To 
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visualize the data, Relative Fluorescence Units (RFU) were plotted against cycle number 
(figure 2). 
 
Reagent Amount in μl Company 
2x iProof HF Master Mix 12.5 Bio-Rad (Hercules, CA) 
Forward primer, 100µM 0.25 Eurofins MWG Operon (Huntsville, AL) 
SYBR Green I Nucleic Acid Gel Stain 0.125 Invitrogen (Carlsbad, CA) 
Molecular Biology Grade Water 4.625 Mediatech (Manassas, VA) 
Table 8. Reagents for RT-PCR. 
 
5μl of exonuclease treatment product and 2.5μl of different barcoded reverse primer for each 
sample (10μM, Integrated DNA Technologies, Coralville, IA) were added to 17.5μl of 
reaction mix (table 8). For primer sequences see annex, table S2. 
Reaction conditions and fluorescence measurement on the Bio-Rad C1000 Thermal Cycler 
with CFX96 Real-Time System module (Bio-Rad, Hercules, CA) were set as follows: 
 
initial DNA denaturation: 98°C for 30sec 
DNA denaturation:   98°C for 10sec 
primer annealing:  60°C for 30sec 
product elongation:  72°C for 20sec 40 cycles 
fluorescence measurement: for every cycle 
product elongation:  72°C for 10sec 
cooling:   4°C until program was stopped 
 
Figure 2. RFU-cycle-diagram. 
Graphs show the amplification of 
exonuclease-treated capture 
products of DNA samples (red), 
WGA samples (blue) and the NTC 
(green). The black line marks the 
21
st
 cycle before the first reaction 
plateaus. 
Red graphs are detectable above 
background in earlier cycles than 
blue graphs indicating that 
amplification in DNA reactions 
started with a higher amount of 
starting material than WGA 
reactions. Thus, capture worked 
more efficiently for DNA samples than WGA samples. 
The green graph increases later than all other graphs, which was expected as the NTC did not include 
any target DNA for capture. The amplification detected was assumed to result from MIPs that 
circularized without the insertion of a target. 
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The cycle number required in PCR was determined graphically as the cycle before the first 
graph reaches the plateau and amplification slows down dramatically. This was the case for 
the 21
st
 cycle marked by the black line in figure 2. 
 
2.2.8 PCR amplification 
 
Exonuclease-treated capture products were added to PCR to amplify the parts of the MIPs 
containing the target copy. Unique 8bp barcodes and universal sequencing adaptors were 
incorporated during the reaction as they were appended to the universal primers. 
 
Reagent Amount in μl Company 
2x iProof HF Master Mix 12.5 Bio-Rad (Hercules, CA) 
Forward primer, 100μM 0.25 Eurofins MWG Operon (Huntsville, AL) 
Molecular Biology Grade Water 4.75 Mediatech (Manassas, VA) 
Table 9. Reagents for PCR master mix. 
 
5μl of exonuclease-treated capture products and 2.5μl of different barcoded reverse primer for 
each sample (10μM, Integrated DNA Technologies, Coralville, IA) were added to 17.5μl of 
reaction mix (table 9). For primer sequences see annex, table S2. 
 
Reaction conditions were set on the GeneAmp PCR System 9700 (Applied Biosystems, 
Carlsbad, CA) as follows: 
 
initial DNA denaturation: 98°C for 30sec 
DNA denaturation:   98°C for 10sec 
primer annealing:  60°C for 30sec 21 cycles 
product elongation:  72°C for 30sec 
final product elongation: 72°C for 2min 
cooling:   4°C until program was stopped 
 
2.2.9 Bead purification 
 
5μl of all PCR reactions were pooled together as every sample could now be identified by its 
unique barcode. Purification was performed using magnetic beads (table 10). 
0.9μl of beads per sample were added to the pooled PCR products, mixed and incubated for 
5min at room temperature. The tube was then placed onto a magnet for 2 min separating the 
PCR products bound to the beads from the solution containing the unincorporated primers and 
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dNTPs. The solution was removed and the beads were rinsed with 70% ethanol allowing to 
incubate for 30sec. Used ethanol was removed and ethanol washing was repeated before 
beads were allowed to dry for 5min. Subsequently, beads were reconstituted in 100μl of 
Elution Buffer, mixed and again placed on the magnet for 1min. The solution containing the 
final library was removed, placed into a new tube and analyzed in gel electrophoresis as 
described in chapter 2.3.2.  
 
Reagent Company 
Agencourt AMPURE XP Beckman Coulter (Brea, CA) 
DynaMag-2 Magnet Invitrogen (Carlsbad, CA) 
Pure Ethanol 200 Proof Decon Laboratories (King of Prussia, PA) 
Buffer EB Qiagen (Venlo, Netherlands) 
Table 10. Materials and reagents for bead purification. 
 
Additionally, the library concentration was measured on the Gemini XPS Fluorescence 
Microplate Reader (Molecular Devices, Sunnyvale, CA) using the Quant-iT dsDNA Assay 




Libraries from this work and another project were combined to create a final pool of 162 
individual capture reactions. This final pool was applied to next generation sequencing on one 
lane of the Illumina HiSeq (San Diego, CA) according to the manufacturer’s instructions.  
The sequencing protocol consisted of two paired-end sequencing reads with a length of 101bp 
and a third read of 8bp to sequence the barcode. For primer sequences see annex, table S3. 
 
2.2.11 Sequence analysis and variant calling 
 
Sequence analysis and variant calling was performed similarly as described in O’Roak et al. 
2012 and Carvill et al. 2013: Each FASTQ file contained sequence information for 
approximately 150 million reads. Sequences of the 101bp runs were trimmed to 76bp which 
resulted in paired-end reads without overlap avoiding double counting of overlapping 
sequence and analysis of lower quality data from the end of the reads. The barcode reads 
correlate to their corresponding 76bp sequences according to their flow cell coordinates. The 
Burrows-Wheeler Aligner (BWA, version 0.5.6) (Li and Durbin 2009; BWA 2010) was then 
used to align the trimmed and barcoded reads to the human genome (hg19/NCBI build 37) 
and to generate a SAM file containing alignment information for the paired-end reads. 
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Subsequently the aligned reads were filtered for the correct target length of 150-154bp and for 
being properly paired and mapped using the SAM flags 83, 99, 147 and 163 (Li et al. 2009a). 
In this step, 4.2% of reads were excluded from further analysis as they did not meet these 
quality criteria. The extension and ligation arm sequences were removed from the sequence 
reads. SAM files were converted to indexed BAM files and applied to SNV and indel calling 
and variant filtration using the Genome Analysis Toolkit (GATK, version 2.1) (McKenna et 
al. 2010; GATK 2012). Clustered variants (window size 10) and variants with an allele 
balance > 0.70 (for heterozygous calls), QD < 5, QUAL < 30 or coverage < 25X were 
excluded. Variants were visually inspected using the Integrative Genomics Viewer (IGV, 
version 2.1.24) (Robinson et al. 2011; IGV 2012) and annotated with Seattle Seq (version 
134) (SeattleSeq 2011). Following a dominant or de novo model, only variants not present in 
the ESP6500 data set (Exome Variant Server 2012) as our control population were assessed 
further. For recessive candidates we considered variants with a frequency of <1% in controls. 
We only considered nonsynonymous, splice-site and frameshift variants. 
 
2.2.12 Quality control 
 
Sequencing coverage calculations of target DNA regions were performed using the GATK 
DepthOfCoverage tool (GATK 2012). Across all samples, on average 93% of bases of each 
target gene were sequenced with a coverage above 25X (annex, figure S1 and S2).  
Former studies applying a similar MIP capture protocol for subsequent sequencing achieved a 
sensitivity of 91-99% for single nucleotide variants (O'Roak et al. 2012; Carvill et al. 2013a). 





2.3 Validation and segregation analysis of rare SNVs 
 
Sanger sequencing was performed to confirm all rare variants not present in the ESP6500 data 
set (Exome Variant Server 2012) that were discovered by targeted resequencing and to 
investigate the available samples of probands’ relatives for these sequence mutations. The 
process from genomic DNA to sequencing data included the following steps: 
 
1. PCR 
2. Gel electrophoresis 
3. PCR product purification 
4. Sequencing reaction 
5. Sequencing product purification 




PCR was performed to specifically amplify the genomic regions encompassing the identified 
variants. Primers were designed according to the NCBI Reference Sequence (National Center 
for Biotechnology Information 2002) for each gene involved (annex, table S4). Each run 
included one NTC per each different amplicon where DNA was replaced by water. 
PCR amplification was implemented in a 25µl reaction containing the following reagents: 
 
Reagent Amount in µl Company 
PCR Master Mix, 2X 12.5 Promega (Fitchburg, WI) 
Forward primer, 10µM 1.0 Integrated DNA Technologies, Coralville, IA 
Reverse primer, 10µM 1.0 Integrated DNA Technologies, Coralville, IA 
Molecular Biology Grade Water 8.5 Mediatech (Manassas, VA) 
Table 11. PCR reagents. 
 
For each sample 2μl of DNA with c = 25ng/μl were added to 23μl of reaction mix. 
 
Reaction conditions were set on the GeneAmp PCR System 9700 (Applied Biosystems, 







initial DNA denaturation: 95°C for 3min 
DNA denaturation:   95°C for 30sec 
primer annealing:  55°C for 30sec  30 cycles 
product elongation:  72°C for 30sec 
final product elongation: 72°C for 5min 
cooling:   4°C until program was stopped 
 
2.3.2 Gel electrophoresis 
 
During electrophoresis, an electrical field is applied so that negatively charged DNA 
molecules migrate to the positive anode. The speed at which a DNA fragment moves through 
the gel depends on its size so that DNA molecules are separated by base pair amounts. DNA 
fragments of known size (DNA Ladder) are used as markers allowing an estimate of PCR 
product length. 
Gel electrophoresis was performed for PCR products and NTCs to evaluate the yield, product 
length accuracy, reaction specificity and contamination of the PCR. Reagents are listed in 
table 12. 
A 1.5% agarose gel was produced by adding 0.75g Agarose to 50ml Tris-Acetate-EDTA 
(TAE) Buffer 1X and briefly heating this mixture in a microwave. After adding 1μl Ethidium 
Bromide Solution (10mg/ml), the mixture was poured into a gel tray using a gel comb to form 
wells. 5μl of each PCR product, NTC and 100bp DNA Ladder (100µg/µl) were mixed with 
1μl Blue/Orange Loading Dye 6X respectively and loaded into the wells of the gel stored in 
TAE Buffer 1X on the Model H5 horizontal gel electrophoresis system (Life Technologies, 
Carlsbad, CA). Electrophoresis was performed at 100V for 30-60 min depending on PCR 
product length. The gel was visualized using the Gel Doc 2000 system (Bio-Rad, Hercules, 
CA) and Quantity One software (version 4.6.5, Bio-Rad, Hercules, CA). 
 
Reagent Company 
Agarose HS, Molecular Biology Grade Denville Scientific (South Plainfield, NJ) 
TAE Buffer 40X (1.6M Tris-Acetate, 40mM EDTA) Promega (Fitchburg, WI) 
Ethidium Bromide Solution (10mg/ml) Promega (Fitchburg, WI) 
100bp DNA Ladder (500µg/ml) New England Bio Labs (Ipswich, MA) 
Blue/Orange Loading Dye, 6X Promega (Fitchburg, WI) 






2.3.3 PCR product purification 
 
To remove unincorporated primers and nucleotides, the enzymes Exonuclease I and 
Thermosensitive Alkaline Phosphatase were added to 5µl of PCR product as part of the 
following reaction mix: 
 
Reagent Amount in µl Company 
Exonuclease 1, E. coli (20U/µl) 0.5 Epicentre (Madison, WI) 
FastAP Thermosensitive Alkaline 
Phosphatase (1U/µl) 
1.0 Thermo Fisher Scientific (Waltham, MA) 
Molecular Biology Grade Water 2.5 Mediatech (Manassas, VA) 
Table 13. Reagents for PCR product purification. 
 
Reaction conditions for the purification reaction were set on the GeneAmp PCR System 9700 
(Applied Biosystems, Carlsbad, CA) as follows: 
 
temperature of enzyme activity: 37°C for 15min 
inactivation of enzymes:  80°C for 15min 
cooling:    4°C until program was stopped 
 
2.3.4. Sanger sequencing reaction 
 
The purified PCR products were sequenced by fluorescence-based cycle sequencing that is 
based on the chain termination sequencing method described by Sanger et al. (Sanger et al. 
1977). In contrast to the original technique using radioactively labeled dideoxynucleotides in 
four different reaction mixes, today’s method uses fluorescently labeled dideoxynucleotides 
and only needs one reaction. 
2µl of purified PCR product were added to 8µl of the following reaction mix (for primer 
sequences see annex, table S4): 
 
Reagent Amount in µl Company 
Big Dye Terminator v3.1 Ready 
RR-100 
2.0 Applied Biosystems (Carlsbad, CA) 
BigDye Terminator v1.1/v3.1 
Sequencing Buffer (5X) 
2.0 Applied Biosystems (Carlsbad, CA) 
Molecular Biology Grade Water 0.8 Mediatech (Manassas, VA) 
Forward or reverse primer, 1µM 3.2 Integrated DNA Technologies (Coralville, IA) 




Reaction conditions for the sequencing reaction were set on the GeneAmp PCR System 9700 
(Applied Biosystems, Carlsbad, CA) as follows: 
 
initial DNA denaturation: 96°C for 1min 
DNA denaturation:   96°C for 10sec 
primer annealing:  50°C for 5sec   25 cycles 
product elongation:  60°C for 4min 
cooling:   4°C until program was stopped 
 
2.3.5. Sequencing product purification 
 
Reagent Company 
MultiScreen-HV plate, pore size 0.45µm Millipore (Billerica, MA) 
Sephadex G-50 Fine GE Healthcare (Little Chalfont, United Kingdom) 
MultiScreen Column Loader, 45µl Millipore (Billerica, MA) 
Molecular Biology Grade Water Mediatech (Manassas, VA) 
PCR Plate Bioexpress (Kaysville, UT) 
MicroAmp 96-Well Tray/Retainer Set Applied Biosystems (Carlsbad, CA) 
MicroAmp 96-Well Base Applied Biosystems (Carlsbad, CA) 
Formamide Amresco (Solon, OH) 
Mineral oil Hoefer (Holliston, MA) 
Round Bottom 96-Well Plate Fisher Scientific (Waltham, MA) 
MultiScreen Centrifuge Alignment Frame Millipore (Billerica, MA) 
96-Well Plate Septa Applied Biosystems (Carlsbad, CA) 
Table 15. Reagents and materials for sequencing product purification. 
 
To remove unincorporated dye and nucleotides, sequencing products were purified using filter 
plates filled with a gel-filtration medium (for materials and reagents see table 15): Each well 
of a MultiScreen-HV plate was filled with Sephadex G-50 Fine using a MultiScreen Column 
Loader and hydrated with 300µl of Molecular Biology Grade Water. The plate was stored for 
two hours at room temperature. A PCR plate was placed into a MicroAmp 96-Well 
Tray/Retainer Set and onto a MicroAmp 96-Well Base. Each well of the PCR plate was filled 
with 10µl of formamide and 10µl of mineral oil. To remove excess water, the hydrated 
MultiScreen-HV plate was centrifuged at 910 x g for 6 min while connected to a Round 
Bottom 96-Well Plate and subsequently placed on top of the PCR plate using a MultiScreen 
Centrifuge Alignment Frame. 10µl of sequencing reaction product were transferred to each 
well of the MultiScreen-HV plate. By centrifuging the attached plates at 910 x g for 6 min, 
the sequencing product ran through the filtration medium and filter of the MultiScreen-HV 
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plate into the formamide of the PCR plate. This plate was sealed with a 96-Well Plate Septa 
and subsequently applied to basecalling. 
 
2.3.6. Basecalling and sequence analysis 
 
Basecalling is an automated process utilizing a combination of capillary electrophoresis and 
fluorescence detection. 
Basecalling was performed on the Applied Biosystems 3130xl Genetic Analyzer with 36cm 
capillary array length and POP-7 polymer (Applied Biosystems, Carlsbad, CA) using the KB 
basecaller software (Applied Biosystems, Carlsbad, CA). 
 
Sequencing data was analyzed with the CLC Main Workbench software (version 6.6.1, CLC 
bio, Aarhus, Denmark). Once sequences were assembled to the corresponding NCBI 
Reference Sequences (National Center for Biotechnology Information 2002), conflicts were 
identified using the software’s secondary peak calling. Additionally to software analysis, all 






2.4 Copy number variation analysis 
 
Array CGH detects copy number differences between a sample and a reference DNA. The 
reference DNA is gained from a healthy individual and assumed to not contain pathogenic 
variants. Sample and reference DNA are differentially labeled with cyanine fluorescent dyes 
(Cy3 and Cy5) and then simultaneously hybridized to an oligonucleotide slide. Every 
oligonucleotide probe represents a locus along the human genome. If sample and reference 
DNA differ in copy number at a certain locus, this will be reflected in fluorescent intensity 
differences of Cy3 and Cy5 for the corresponding probe. The fluorescence is excited and 
measured by a laser scanner. To visualize the data the log2 of fluorescence intensity ratios is 
plotted against the loci of probes. 
 
Genome-wide array CGH was applied to the identification of rare CNVs in all patients from 
cohort 2. Arrays with rare non-recurrent CNVs were replicated for validation. Where 
available, parental DNA was investigated to determine whether the CNV had arisen de novo 
or was inherited. 
Array platforms used had a median probe spacing of 13kb for 4x180K arrays (Agilent 
Technologies, Santa Clara, CA) and 2.1kb for 1M arrays (Agilent Technologies, Santa Clara, 
CA) with a slightly higher probe coverage within RefSeq genes (National Center for 




Labeling was performed using the Dual-Color DNA Labeling Kit (NimbleGen, Madison, WI, 
table 16). Reference DNA originated from a male Caucasian and was extracted from an EBV-
transformed B-lymphocyte cell line. 
The labeling process as well as isopropanol precipitation and ethanol washing were carried 
out following the manufacturer’s instructions (Roche NimbleGen 2011, chapter 3) with minor 
modifications: The initial sample and reference DNA amounts were changed from 500ng to 
250ng. Accordingly, the amounts of all labeling reagents, isopropanol and ethanol were 
halved. 
The dried pellets were gradually rehydrated with 15-35 μl of water per 250ng starting material 
to reach a DNA concentration around 2000ng/μl measured on the NanoDrop 2000 





Dual-Color DNA Labeling Kit 
- PCR Grade Water 
- Random Primer Buffer 
- Cy3 Random Nonamers 
- Cy5 Random Nonamers 
- Klenow Fragment 
  (3’->5’ exo-), 50 U/μl 
- dNTP Mix 
  (10mM each dNTP) 
- Stop Solution 
NimbleGen (Madison, WI) 
2-Mercaptoethanol Bio-Rad (Hercules, CA) 
2-Propanol (Isopropanol) Sigma Aldrich (St. Louis, MO) 
Pure Ethanol 200 Proof Decon Laboratories (King of Prussia, PA) 




Equal amounts of labeled sample and reference DNA were added together as specified in 
table 17 and prepared for hybridization with the Agilent Oligo aCGH/ChIP-on-Chip 
Hybridization Kit (table 18) following the manufacturer’s instructions (Agilent Technologies 
2011, chapter 4, step 3). Cot-1 DNA was not used and its volume replaced by water. 
 
Labeled DNA 4x180K array 1M array 
Sample DNA 10µg 25µg 
Reference DNA 10µg 25µg 
Table 17. Amounts of labeled DNA prepared for hybridization. 
 
Reagent Company 
Oligo aCGH/ChIP-on-Chip Hybridization Kit 
- 2X Hi-RPM Hybridization Buffer 
- 10X Oligo aCGH/ChIP-on-Chip Blocking Agent 
Agilent Technologies (Santa Clara, CA) 
Table 18. Reagents for hybridization preparation. 
 
Microarray loading was conducted as specified by Agilent Technologies (Agilent 
Technologies 2011, chapter 5, step 1) using the following materials: 
 
Material Company 
Gasket slide, 4 microarrays/slide format Agilent Technologies (Santa Clara, CA) 
Gasket slide, 1 microarray/slide format Agilent Technologies (Santa Clara, CA) 
SurePrint G3 Human CGH Microarray Kit, 4x180K Agilent Technologies (Santa Clara, CA) 
SurePrint G3 Human CGH Microarray Kit, 1x1M Agilent Technologies (Santa Clara, CA) 
Microarray Hybridization Chamber Kit Agilent Technologies (Santa Clara, CA) 




Loaded 4x180K arrays were incubated at 65°C for 40 hours, 1x1M arrays at 65°C for 48 
hours in the G2545A Hybridization Oven (Agilent Technologies, Santa Clara, CA) with 




After hybridization, the microarray slides were washed to remove excess hybridization 
solution. Washing was performed as described in the Agilent protocol (Agilent Technologies 
2011, chapter 5, step 2 and 3, washing procedure A) using the materials and reagents listed in 
table 20. Subsequently, slides were placed in a slide holder and covered with an ozone-barrier 
slide to avoid ozone-induced degradation of Cyanine dyes. 
 
Reagent/material Company 
Oligo aCGH/ChIP-on-Chip WB1 Agilent Technologies (Santa Clara, CA) 
Oligo aCGH/ChIP-on-Chip WB2 Agilent Technologies (Santa Clara, CA) 
Slide holder Agilent Technologies (Santa Clara, CA) 
Ozone-Barrier Slide Cover Kit Agilent Technologies (Santa Clara, CA) 
Table 20. Washing materials and reagents. 
 
2.4.4 Scanning and Feature Extraction 
 
Microarray slides were scanned on a G2505C DNA Microarray Scanner (Agilent 
Technologies, Santa Clara, CA) using the Agilent Scan Control software (version A.8.4.1) 
with the preset Agilent G3 CGH/CNV/ChIP scan profile (resolution 3µm). 
The output image file was further processed by the Agilent Feature Extraction software 
(version 10.7.3.1) using the default CGH_107_Sep09 protocol. 
 
2.4.5 Data processing and CNV calling 
 
Further data processing and analysis were performed using the Agilent Genomic Workbench 
software (standard edition, version 5.0.14). Log2 ratios for each array were normalized 
applying the centralization algorithm with bin size 10 and centralization threshold 6.0. Intra-
array replicates were combined using the corresponding Genomic Workbench function. 
Saturated and non-uniform features were excluded from further analysis. 
The Derivative Log Ratio Spread (DLRS) is an estimate of signal noise and was used for 
quality control. It describes the standard deviation of the probe-to-probe log2 ratio difference, 
averaged across the genome and divided by   . All arrays had a DLRS ≤ 0.3 and 26 of 36 
arrays had a DLRS < 0.2 defined as excellent by Agilent Technologies. 
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CNVs were called applying the Aberration Detection Method 2 (ADM-2) algorithm provided 
by Genomic Workbench with a threshold of 6.0. Additionally, all arrays were visually 
inspected for CNVs. 
 
2.4.6 Filtering CNV calls 
 
Aberration filters in Genomic Workbench were set so that only CNVs containing at least 5 
probes with a minimum average absolute log ratio of 0.5 were reported. 
Subsequently, variants were filtered as previously described (Mefford et al. 2011) to eliminate 
CNVs that did not overlap any RefSeq genes (National Center for Biotechnology Information 
2002), lay entirely within segmental duplications or had a >50% overlap with a CNV detected 
in 4,519 published controls (Itsara et al. 2009; Shaikh et al. 2009). The last criterion was not 
applied to established hotspot CNVs known to rarely occur in healthy controls. 
All filtered CNVs were assessed by visual analysis in Genomic Workbench. 
 
2.5 Deletion breakpoint mapping 
 
To evaluate if HNRNPU, a candidate gene for epilepsy and ID (Caliebe et al. 2010; Ballif et 
al. 2012; Thierry et al. 2012), was included in the 1q44 deletion of patient #2, deletion 
breakpoints were refined using the Takara LA PCR Kit (version 2.1, Takara Bio, Otsu, Japan) 
according to the manufacturer’s instructions. Primers were designed to amplify the genomic 
region encompassing the deletion breakpoints (annex, table S5). Length estimation of PCR 
fragments in gel electrophoresis allowed to refine the breakpoint regions. Gel electrophoresis 
was performed as described in chapter 2.3.2 using a 0.6% agarose gel and 1kbp DNA ladder 
(New England Bio Labs, Ipswich, MA). 
 
2.6 Microsatellite analysis 
 
Microsatellite analysis was used to confirm maternity and paternity for parents of individuals 
with de novo variants in CNV analysis or targeted resequencing. Patient #2 did not undergo 
microsatellite analysis as she carried further CNVs that were either maternally or paternally 
inherited. Microsatellite analysis was performed using the PowerPlex S5 Sytem (Promega, 





2.7 Evaluation of pathogenicity 
 
2.7.1 Pathogenicity of rare SNVs 
 
Only nonsynonymous, splice-site or frameshift variants not present in 6500 controls were 
analyzed (Exome Variant Server 2012). Variants were assumed to be pathogenic if they had 
arisen de novo or segregated with the disorder. SCN1A mutations were also evaluated as 
pathogenic if the SCN1A variant database included mutations at the same cDNA position in 
affected individuals (SCN1A variant database 2009). Additionally, we used the freely 
available online tools PolyPhen-2 (Adzhubei et al. 2010; PolyPhen-2 2010) and SIFT (Ng and 
Henikoff 2001; SIFT 2001) to assess the pathogenicity of missense mutations. 
Rare variants, where parental DNA was unavailable for analysis, would have been interpreted 
as likely pathogenic if they led to protein truncation (splice-site, frameshift and nonsense 
changes). However, such variants were not identified in this study. 
All remaining variants were interpreted as of unknown significance. 
 
2.7.2 Pathogenicity of rare CNVs 
 
Based on previous CNV studies (Mefford et al. 2011) and on guidelines for the interpretation 
of clinical array CGH results in patients with autism, ID or CGA (Miller et al. 2010), we 




pathogenic - known pathogenic CNVs 
- CNVs including known epilepsy genes 
- de novo deletions 
likely pathogenic - de novo duplications 
- CNVs > 1 Mb (inherited or of unknown inheritance) 
of unknown significance - all remaining CNVs 
Table 21. Evaluation of pathogenicity for rare CNVs. 
 
2.8. Detailed phenotyping 
 
Clinical documentation was reviewed for epilepsy, developmental and general medical 
history for all patients with rare SNVs, pathogenic or likely pathogenic CNVs. Furthermore, 






3.1 Targeted resequencing 
 
23 (27%) of 84 individuals with recurrent FS or fever-associated epilepsies carried a rare 
possibly damaging SNV, hence a nonsynonymous, splice-site or frameshift mutation not 
present in 6500 controls (Exome Variant Server 2012). Five variants occurred de novo and 
nine variants were inherited of which three segregated with the disorder. Nine variants were 
of unknown inheritance. We did not identify any deleterious recessive mutations. 
All variants were validated using Sanger sequencing. Microsatellite analysis confirmed 
maternity and paternity for the parents of individuals with de novo mutations. 
 
3.1.1 Pathogenic rare SNVs 
 
We detected 10 pathogenic variants all occurring in known epilepsy genes (table 22). 
 
Eight pathogenic variants occurred in SCN1A. Surprisingly, five of eight patients with newly 
identified SCN1A variants were previously tested negative for mutations in this gene using 
Sanger sequencing. 
Three mutation carriers presented with FS+ or SIGEI in the context of GEFS+: 
 
Figure 3. Pedigree of family 1 with GEFS+ and 
SCN1A mutation. 
FS+ = febrile seizures plus. The arrow indicates the 
proband. + carries the mutation; - does not carry the 









Family 1 (patient B) involved the proband, mother and sister with „FS+ afebrile“ and the 
unaffected father and grandparents (figure 3). The SCN1A mutation was maternally inherited. 
The also affected sister with recurrent FS in childhood and afebrile GTCS in youth did not 
carry the variant. We nevertheless evaluated the variant as pathogenic considering the sister’s 
clinical presentation a phenocopy. Epilepsy and especially FS are relatively frequent in the 
population and might occur in GEFS+ pedigrees but be due to different genetic risk factors 




Figure 4. Pedigree of family 2 with GEFS+ and SCN1A mutation. 
FS = febrile seizures; GGE = genetic generalized epilepsy; GTCS = generalized tonic-clonic seizures; 
SIGEI = severe idiopathic generalized epilepsy of infancy. The arrow indicates the proband. + carries 
the mutation; - does not carry the mutation; not marked: not investigated for variants in SCN1A 
 
Family 2 (patient C) comprised the proband and his brother with SIGEI, the mother with GGE 
and the unaffected father (figure 4). The maternally inherited SCN1A mutation also occurred 
in the affected brother strongly suggesting pathogenicity of the variant. The maternal 
grandfather had unspecified seizures in childhood. A paternal uncle had FS in early 
childhood. The father, aunts, uncles and grandparents were not tested for SCN1A variants. 
 
Patient D of family 3 presented with FS+ and additional myoclonic and atonic seizures in 
accordance with myoclonic-astatic epilepsy (MAE). The SCN1A mutation was paternally 
inherited and segregated with recurrent FS in brother and sister and with FS+ in the proband 
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and his father (figure 5). The also affected mother (recurrent FS) did not carry the mutation, 
but was interpreted as a phenocopy. Moreover, five additional paternal relatives presented 
with a single or recurrent FS indicating that the variant segregated from the parternal side of 
the family. However, we did not investigate these individuals for mutations in SCN1A. 
 
We identified de novo SCN1A mutations in three patients and SCN1A variants of unknown 
inheritance in two patients with typical or atypical Dravet syndrome. For the latter, the 
SCN1A variant database included mutations at the same cDNA position in patients with 
Dravet syndrome supporting the assumption of pathogenicity for these variants (SCN1A 
variant database 2009). 
 
One pathogenic de novo mutation was identified in GABRA1 and SCN2A respectively. Both 
variants were missense mutations and predicted to be damaging by PolyPhen-2 and SIFT. 
The GABRA1 mutation was identified in a patient with hemiclonic status epilepticus while 
bathing and one generalized seizure during febrile illness in the first year of life. In infancy, 
the patient’s phenotype was consistent with Dravet syndrome. However, later on, frequent 
absence seizures, mild ID, long periods of seizure-freedom as well as 3/s-spike waves and 
photosensitivity in the EEG suggested a diagnosis in favor of GGE. 
The SCN2A mutation occurred in an individual with a diagnosis of SCN1A-negative Dravet 
syndrome, but a febrile infection-related epilepsy syndrome (FIRES) was also taken into 
consideration. The first seizures occurred at the age of three years during a febrile illness 
without an identifiable focus of infection. Two weeks after seizure onset, the child developed 
catastrophic epilepsy with several therapy-resistant convulsive seizures per hour. This 
biphasic clinical course with a short interval between initial seizures in the context of febrile 
illness and acute period of high seizure activity would be typical of FIRES. However, the 
patient’s outcome was better than in most indiviudals with FIRES that frequently present with 
therapy-refractory focal epilepsy and a vegetative or minimally conscious state (van Baalen et 
al. 2010): The development before seizure onset was unremarkable. The child experienced 
regression at seizure onset and presented with moderate ID over time. The patient 
predominantly had generalized seizures including myoclonic seizures that are common in 





Figure 5. Pedigree of family 3 with GEFS+ and SCN1A mutation. 
FS = febrile seizures; FS+ = febrile seizures plus; GTCS = generalized tonic-clonic seizures; MAE = myoclonic-astatic epilepsy. The arrow indicates the 




Patient (sex) Gene 
with 
variant 













Patient A (♂) 
 










Patient B (♀) 
 
SCN1A maternal, S does 
not carry the 
mutation 
M and S: FS+ afebrile 
(recurrent FS in 
childhood, afebrile GTCS 
in youth); F: unaffected 
(figure 3) 










Patient C (♂) 
 
SCN1A maternal, B also 
carries the 
mutation 
M: GGE with GTCS; 
F: unaffected; B: SIGEI 
(figure 4) 










Patient D (♂) 
 
SCN1A paternal, B and 
S also carry the 
mutation 
F: FS+ afebrile (recurrent 
FS, three afebrile GTCS); 
M, B, S: recurrent FS 
(figure 5) 












Patient E (♀) 
 
SCN1A unknown maternal grandmother: 
two FS, apart from that no 













Patient F (♀) 
 
SCN1A de novo paternal aunt: seizures 
after vaccination, apart 




unknown splice-site NA NA pathogenic 
(SCN1A 
database)  
Patient G (♀) 
 




stop-gained NA NA pathogenic 
(SCN1A 
database) 
Patient H (♀) 
 




stop-gained NA NA pathogenic 
(SCN1A 
database) 
Patient I (♂) 
 




stop-gained NA NA pathogenic  
Patient J (♀) 
 










Table 22. Pathogenic SNVs identified in targeted resequencing of 84 patients. 
B: brother; F: father; FS = febrile seizures; FS+ = febrile seizures plus; GGE = genetic generalized epilepsy; GTCS = generalized tonic-clonic seizures; M: 
mother; S: sister; SIGEI = severe idiopathic generalized epilepsy of infancy, SCN1A database = entry in the SCN1A variant database included affected individuals 
with mutations at the same cDNA position; 
a
(Adzhubei et al. 2010; PolyPhen-2 2010); 
b




3.1.2 Rare SNVs of unknown significance 
 
We identified 13 rare variants of unknown significance (table 23). All variants were missense 
mutations not segregating with the disorder or of unknown inheritance. 
 
Six variants occurred in known epilepsy genes. An individual with FS+ carried a GABRG2 
mutation predicted as damaging by PolyPhen-2 and SIFT, but of unknown inheritance. A 
SCN1B mutation predicted as probably damaging was detected in a patient with SCN1A-
negative Dravet syndrome. Unfortunately, parental DNA was unavailable for this individual. 
We identified two SLC2A1 variants. One mutation occurred in a patient with SIGEI and was 
evaluated as benign by both online tools. The other SLC2A1 variant was detected in a patient 
with FS+ and inherited from an unaffected mother. The father and sister with recurrent FS did 
not carry the mutation suggesting that other genetic risk factors might contribute to the 
epilepsy phenotypes in this family. Mutations in SPTAN1 were found in a patient with 
SCN1A-negative Dravet syndrome (inherited from an unaffected mother) and an individual 
with recurrent FS (of unknown inheritance). PolyPhen-2 and SIFT gave contradictory 
pedictions for these variants.  
 
Seven variants of unknown significance occurred in candidate epilepsy genes. An EPHA6 
variant of unknown inheritance was identified in a patient with mild FS+ and predicted as 
benign by both online tools. ADAM22 mutations occurred in a patient with FS+ and in an 
individual with SCN1A-negative Dravet syndrome and had contradictory predictions for 
pathogenicity by PolyPhen-2 and SIFT. The variants were inherited from an unaffected father 
and a mother with unknown medical history respectively. A mildly affected individual with 
FS+ and a patient with SCN1A-negative Dravet syndrome each carried a DLGAP2 variant 
predicted as benign. The mutation of the FS+ patient was inherited from an unaffected mother 
and also occurred in both unaffected sisters arguing against pathogenicity of the variant. The 
other DLGAP2 mutation was of unknown inheritance. Mutations with contradictory 
pathogenicity predictions were identified in DLGAP1 in a patient with FS+ and in ADAM23 
in a patient with SCN1A-negative Dravet syndrome. The DLGAP1 variant was inherited from 
an unaffected mother. The ADAM23 mutation was of unknown inheritance. 
 
3.1.3 Phenotypes of patients with rare SNVs 
 
Table 24 gives detailed information on the phenotypes of all patients with rare variants. 
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Patient (sex) Gene 
with 
variant 









SIFTb Evaluation of 
pathogenicity 
Patient K (♂) 
 










Patient L (♀) 
  
SCN1B unknown M: unspecified 
epilepsy in infancy, 
apart from that no 












Patient M (♂) 
 
SLC2A1 maternal, S does 
not carry the 
mutation 
M: unaffected; 
F and S: recurrent FS 










Patient N (♀) 
  
SLC2A1 unknown no neurological 










Patient O (♂) 
 
SPTAN1 unknown no epilepsy in family; 












Patient P (♀) 
  










Patient Q (♂) 
 











Patient R (♂) 
  










Patient S (♀) 
  









Patient T (♂) 
 










Patient U (♂) 
 
DLGAP2 maternal, S1 and 
S2 also carry the 
mutation 
M, S1and S2: 










Patient V (♂) 
  









Patient W (♂) 
 









Table 23. Rare SNVs of unknown significance identified in targeted resequencing of 84 patients. 
B: brother; F: father; FS = febrile seizures; low conf. = low confidence; M: mother; S: sister; 
a
(Adzhubei et al. 2010; PolyPhen-2 2010); 
b































Patient A (♂) 
  












normal, mild ID 
(no) 
8 mo: right centro-parietal foci and 
hypersynchronous activity; 2 y: 3/s-
SW and theta activity; 19 y: 
borderline background slowing and 
photosensitivity °II 






























at onset: NA; 2 y: theta activity, 
























2 y: normal; 3 y: irregular SW; 








Patient D (♂) 
 













3 y: generalized SW, polySW; 8 y: 
pronounced central µ-rhythm, 
single sharp waves with left 








Patient E (♀) 
 



















8 mo: normal NA - SCN1A 












Abs, Ast, T 





at onset: normal; 2 y: theta activity, 
3/s and irregular SW; 23 y: theta 
activity, irregular SW and SSW 
NA - SCN1A 

















































6 mo: normal; 3 y: background 
slowing; 5 y: generalized slowing 





16 mo: slightly 
asymmetric 
occipital lobes 
(left > right) 
- SCN1A 















periods of one 




3 y: background slowing, diffuse 
theta-delta-activity; 4 y: sharp 
waves, SSW and spikes with right 
fronto-parietal emphasis, 4/s-
activity 
3 y: normal - SCN1A 
Patient I (♂) 
 




















6 mo: normal; 8 mo: theta and 
intermittent delta activity, several 
generalized spikes; 19 y: diffuse 
theta activity, irregular generalized 
SW under hyperventilation 
18 y: normal 15 y: VNS 
implantation 
SCN1A 






















diffuse background slowing, 
generalized spikes, polyspikes and 
(poly)SW 
normal mild ataxia SCN2A 
Patient K (♂) 
 














at onset: NA; 2y: normal; 10 y: 
small centroparietal and left 
temporal sharp waves; 13 y: normal 
NA - GABRG2 















normal, mild ID 
(unknown) 



































Patient M (♂) 
 






ongoing Abs normal, speech 
delay (no) 
at onset: not done; 
4 y: generalized SW, left and single 
right frontal sharp waves; 6 y: 
generalized polySW and 3/s SW, 
right fronto-temporo-parietal sharp 
and polysharp waves 



























at onset: not done; 
2 y: theta-delta-activity, stretches of 
right- or left-hemispheric slow 
waves; 15 y: theta-delta-activity, 
single multiregional sharp waves 
under hyperventilation 
2 y: normal ataxia SLC2A1 
Patient O (♂) 
 
 
5 y recurrent FS unknown, 
recurrent FS 
FS (last one 






at onset: NA; 22 mo: theta activity; 
5 y: background slowing (3/s-
activity) under hyperventilation  
NA - SPTAN1 























Patient Q (♂) 
 
 














first EEGs: normal; 7 y: irregular 
generalized SW and polySW, 
photosensitivity °IV; 7y: normal 
(under VPA) 
6 y: normal - ADAM22 




unknown unknown unknown unknown unknown unknown unknown ADAM22 









at sleep onset 
normal, mild to 
moderate ID 
(unknown) 





Patient T (♂) 
 
 










at onset: NA; 13 mo: normal; 8 y: 
normal 


































Patient U (♂) 
 
 































at onset: normal; 2y: generalized 
SW, diffuse slowing 
normal ataxia DLGAP2 
Patient W (♂) 
 
 
15 y FS+ afebrile first year of 







at onset: NA; 14 y: single SW 
complexes under hyperventilation, 
photosensitivity °IV; 15 y: 
photosensitivity °IV 
NA - EPHA6 
Table 24 (continued). Clinical features of patients with rare SNVs. 
Abs = absence seizures; Ast = astatic seizures; At = atonic seizures; BC = bilateral convulsive seizure; DS = Dravet syndrome; FC = focal clonic seizures; FDS = focal 
dyscognitive seizures; FIRES = febrile infection-related epilepsy syndrome; FS = febrile seizures; FS+ = febrile seizures plus; GTCS = generalized tonic-clonic seizures; GTS = 
generalized tonic seizure; HRMCA = high resolution melting curve analysis; ID = intellectual disability; M = myoclonic seizures; mo = months; NA = not available; polySW = 
polyspike waves; SE = status epilepticus; SIGEI = severe idiopathic generalized epilepsy of infancy; SSW = sharp slow waves; SW = spike waves; T = tonic seizures; VPA = 




3.2 Copy number variation analysis 
 
3.2.1 Rare CNVs 
 
We identified 13 rare CNVs in eight (22%) of 36 patients (table 25) including four individuals 
with a single, three patients with two and one patient with three CNVs. Three CNVs occurred 
de novo, four variants were inherited and six CNVs were of unknown inheritance. 
Microsatellite and CNV segregation analysis confirmed maternity and paternity for the 
parents of individuals with de novo mutations. 
 
Four patients carried pathogenic CNVs previously described in neurodevelopmental disorders 
(figure 6). Pathogenic variants included two recurrent CNVs, namely a 1q21.1 duplication in 
patient #8 with SCN1A-negative Dravet syndrome and a distal 16p11.2 deletion in patient #3 
with unclassified fever-associated epilepsy, ID, autism, generalized muscular hypotonia and 
macrocephaly. Patient #2 with unclassified fever-associated epilepsy, ID, dysmorphic 
features, and short stature carried a 1q44 deletion. This individual presented with two 
additional rare inherited CNVs of unknown significance including a duplication at 6q23.3 and 
a deletion at 7p22.1. Furthermore, we identified a maternally inherited pathogenic 14q23.3 
deletion interrupting GPHN and a 4q28.3 deletion of unknown significance in patient #1 with 
FS+. 
Three likely pathogenic CNVs were discovered in two individuals (figure 7). Patient #4 with 
FS+ presented with a 1.6Mb duplication at 3q13.11 including ALCAM and CBLB. Two likely 
pathogenic de novo CNVs were identified in patient #5 with atypical Dravet syndrome, a 
191kb duplication at 7p14.2 including ELMO1 and a 217kb duplication at 18q12.2 
comprising five zinc finger genes. 
We discovered three additional duplications at 11p15.1, 1p22.3 and 4p15.31 in two patients. 
These were of unknown significance. 
 
The breakpoints of the 1q44 deletion in patient #2 were narrowed down to chr1: 243090300-
243093300 and chr1: 244408023-244411023 (NCBI Build 36), interrupting HNRNPU by 





Pat. Epilepsy phenotype ID, autism, CGA CNV, 
chr location 
Coordinates 







Inheritance Evaluation of 
pathogenicity 
#1 FS+ afebrile - del, 4q28.3  139.29-139.49 197 SLC7A11 not in mother of unknown significance 
   del, 14q23.3 66.18-66.27 85 GPHN M pathogenic 
#2 unclassified fever-
associated epilepsy 










de novo pathogenic 
   dup, 6q23.3 135.89-136.07 184 MIR548H4, C6orf217 M of unknown significance 













#4 FS+ prolonged borderline ID 
b
 dup, 3q13.11 106.11-107.73 1623 ALCAM, CBLB not in mother likely pathogenic 
#5 SCN1A-negative atypical 
Dravet syndrome 
ID dup, 7p14.2 36.93-37.12 191 ELMO1 de novo likely pathogenic 
   dup, 18q12.2 31.02-31.24 217 ZNF397, ZNF397OS, 
ZNF271, ZNF24, 
ZNF396 
de novo likely pathogenic 
#6 SCN1A-negative Dravet 
syndrome 
ID, autism dup, 11p15.1 21.30-21.39 92 NELL1 M of unknown significance 
#7 SCN1A-negative Dravet 
syndrome 
ID, microcephaly dup, 1p22.3 87.17-87.28 115 HS2ST1 unknown of unknown significance 
   dup, 4p15.31 21.87-22.73 855 GPR125, GBA3 unknown of unknown significance 
#8 SCN1A-negative Dravet 
syndrome 





CHD1L, BCL9, ACP6, 
GJA5, GJA8, GPR89B 
unknown pathogenic 
Table 25. Rare CNVs identified in 36 patients with SCN1A-negative fever-associated epilepsies. 
CGA, congenital anomalies; F, inherited from father; FS+, febrile seizures plus; ID, intellectual disability; M, inherited from mother; 
a
 HNRNPU was shown 
to be interrupted by the deletion by refining the breakpoints with long-range PCR and gel electrophoresis to chr1: 243090300-243093300 and 
chr1: 244408023-244411023 (NCBI Build 36); 
b
 full scale intelligence quotient of 75 in the Hamburg Wechsler Intelligenztest für Kinder IV as the German 
adaption of Wechsler Intelligence Scale for Children IV (Daseking et al. 2007); 
c
 (National Center for Biotechnology Information 2002); (table as published in 




Figure 6. Array CGH results for all pathogenic CNVs detected in 36 patients. patient #1, del 
14q23.3 (A); patient #2, del 1q44 (B); patient #3, distal del 16p11.2 (C); patient #8, dup 1q21.1 (D). 
Probe log2 ratios are plotted against the loci of probes and depicted by vertical lines: between -0.5 and 
0 colored gray, between 0 and 0.5 colored black, < -0.5 colored red, > 0.5 colored green. RefSeq genes 
(National Center for Biotechnology Information 2002) are shown in blue. (figure as published in 





Figure 7. Array CGH results for all likely pathogenic CNVs detected in 36 patients. patient #4, 
dup 3q13.11 (A); patient #5, dup 7p14.2 (B); patient #5, dup18q12.2 (C). Probe log2 ratios are plotted 
against the loci of probes and depicted by vertical lines: between -0.5 and 0 colored gray, between 0 
and 0.5 colored black, < -0.5 colored red, > 0.5 colored green. RefSeq genes (National Center for 
Biotechnology Information 2002) are shown in blue. (figure as published in Hartmann et al 2015, 
license agreement with John Wiley and Sons available) 
 
3.2.2 Phenotypes of patients with pathogenic CNVs 
 
Phenotype descriptions were published in Hartmann et al. 2015 (agreement with John Wiley 
and Sons available): 
 
“Patient #1 (FS+ afebrile) 
At the age of 17 months, the patient experienced a febrile GTCS in the course of 
gastroenteritis. A first afebrile generalized tonic seizure occurred in the fourth year of life. 
Five months later, the patient presented with a second afebrile GTCS. Long-term medication 
was not started. A first EEG at three and a half years was unremarkable, while a postictal 
follow-up EEG after the second afebrile seizure revealed intermittent slowing in the right 
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occipital region. A subsequent follow-up EEG was unremarkable. MRI was not performed. 
Psychomotor development was unremarkable. Family history was negative with the exception 
of a maternal aunt with unclassified epilepsy. Array CGH identified a maternally inherited 
14q23.3 deletion interrupting GPHN and a 4q28.3 deletion of unclear inheritance. Paternal 
DNA was not available. 
 
Patient #2 (unclassified fever-associated epilepsy) 
From the age of nine months, the patient experienced recurrent GTCS with fever. Brief 
absence-like events with extension of the neck occurred up to three times a day starting at the 
age of 18 months, reminiscent of eyelid myoclonias with absences. In addition, myoclonic 
seizures were suspected, but could not be recorded. Frequency of GTCS decreased under 
pharmacotherapy with valproic acid and ethosuximide and the patient was seizure-free from 
the age of three to five. One break-through seizure resulted in an increase of valproic acid. At 
the last consultation at the age of seven, the patient had been seizure-free for about two years. 
Multiple EEGs during the first year of life showed generalized spike-wave discharges. EEGs 
from the age of two onwards showed no epileptiform activity, but mild to severe background 
slowing. An MRI performed at the age of two years showed bilateral hippocampal 
malrotation and a pineal cyst. The findings were not interpreted as causal. Developmental 
delay was first noted at four months. Unaided sitting was achieved at 14 months, supported 
walking and single words were present at two years. At the last consultation at the age of 
seven years, the patient had moderate to severe ID. The patient also had short stature (below 
the third percentile), head circumference was between the third and tenth percentile. 
Furthermore, the patient had mild dysmorphic features including a thin upper lip, smooth 
philtrum, wrinkled skin on the hands and cutaneous syndactyly of second and third toe. 
Family history was negative for epilepsy. Array CGH revealed a de novo 1q44 deletion as 
well as a 6q23.3 duplication inherited from the mother and a 7p22.1 deletion inherited from 
the father. 
 
Patient #3 (unclassified fever-associated epilepsy) 
Between the ages of one to two years, the patient experienced recurrent generalized seizures 
during fever. The first afebrile GTCS occurred at the age of three. Carbamazepine was 
initiated at the age of five, resulting in temporary seizure control until the age of seven, when 
recurring afebrile seizures were refractory to carbamazepine and oxcarbazepine. Seizures 
were finally controlled by valproic acid in combination with levetiracetam. During the last 
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consultation at the age of nine years, the patient had been seizure free for four months. Based 
on clinical grounds, a diagnosis of FS+ could be considered given the prominence of fever-
related attacks. However, given the additional syndromic features, we refrained from making 
this diagnosis. An EEG at the age of one was unremarkable, follow-up EEGs showed severe 
background slowing and multiregional sharp-waves. MRIs in infancy and at the age of eight 
were unremarkable. The patient had a diagnosis of autism, severe ID and generalized 
muscular hypotonia present from birth. Independent walking and single words were present at 
the age of four. The patient had macrocephaly (>97th percentile), but no dysmorphic features. 
Family history for epilepsy was negative except for a maternal aunt with unclassified epilepsy 
in childhood. The patient had previous negative testing for Fragile X, Angelman syndrome 
and spinal muscular atrophy (SMN1). Array CGH detected a distal 16p11.2 deletion of 
unknown inheritance. 
 
Patient #8 (SCN1A-negative Dravet syndrome) 
The patient presented with a convulsive febrile status epilepticus at the age of ten months. On 
valproic acid, the patient experienced four simple FS from twelve months to the age of two 
and a half years. Subsequently, a second febrile convulsive status epilepticus lateralized to the 
right side occurred. Lamotrigine was added to valproic acid, resulting in afebrile and febrile 
GTCS every three months. At the age of six, Lamotrigine was replaced by topiramate, 
resulting in a reduced seizure frequency of two afebrile and one febrile GTCS between the 
age of seven and twelve at the last consultation. First EEGs were unremarkable. From the age 
of six onwards, EEGs showed diffuse slowing but no epileptiform discharges. An MRI 
performed at the age of seven was unremarkable. Development before seizure onset was 
reported as normal. Later on, the patient presented with ID; non-verbal IQ (Leiter scale) 
[(Leiter 1982)] at the age of six was 56. Independent walking was achieved with two and a 
half years. The patient did not have dysmorphic features, macrocephaly or autism. Family 
history was negative for epilepsy and other neurological disorders. Array CGH showed a 
pathogenic 1q21.1 duplication of unknown inheritance.” 
 
3.2.3 Phenotypes of patients with likely pathogenic CNVs 
 
Phenotype descriptions were published in Hartmann et al. 2015 (agreement with John Wiley 




“Patient #4 (FS+ prolonged) 
The patient presented with several febrile seizures per year starting in the second year of life, 
which lasted until year eight. Seizures were intermittently treated with Primidone, which was 
eventually discontinued due to side effects. From year three onwards, the patient did not take 
antiepileptic medication. An EEG at the age of five years was unremarkable. An EEG at age 
15 showed photosensitivity grade I-II. A subsequent EEG was unremarkable. An MRI at age 
14 did not show any pathologic findings. The patient underwent physiotherapy, occupational 
therapy and speech therapy as development was slightly delayed. Speech delay persisted 
during childhood and the patient was diagnosed with dysgrammatism and dyslalia. The 
patient attended a regular school. In adolescence, psychological testing showed below-
average intelligence (HAWIK-IV full scale IQ: 75, CFT20 full scale IQ: 82) [(Cattell and 
Weiß 1978; Daseking et al. 2007)]. At the age of 14, the patient developed an undifferentiated 
somatoform disorder that presented with paresthesias of the legs, transient vertigo, headaches, 
exertional dyspnea and abdominal pain and was treated with psychotherapy. Family history 
was positive for childhood epilepsy in the mother. Array CGH identified a 1.6 Mb 3q13.11 
duplication of unknown inheritance comprising the ALCAM and CBLB genes. The mother did 
not carry the CNV. Paternal DNA was not available. 
 
Patient #5 (SCN1A-negative atypical Dravet syndrome) 
This patient presented with GTCS at the age of 11 months. Soon, she developed a therapy-
resistant epilepsy including afebrile and occasional febrile GTCS, multiple myoclonic 
seizures a day, absence seizures, and frequent status epilepticus. She had severe intellectual 
disability and was initially diagnosed with Dravet syndrome. However, fever sensitivity was 
not as pronounced as would be expected in this syndrome. An EEG at the age of 14 years was 
unremarkable, earlier EEGs were unavailable for review. Family history was negative for 
febrile seizures and epilepsy. Array CGH identified two de novo duplications at 7p14.2 






4.1 Diagnostic yield of targeted resequencing and CNV analysis 
 
We performed targeted resequencing and genome-wide CNV analysis in individuals with 
recurrent FS and fever-associated epilepsies. We identified rare SNVs in 23 (27%) of 84 
patients and rare CNVs in 8 (22%) of 36 individuals. In 10 (12%) of 84 patients and 4 (11%) 
of 36 individuals, SNVs and CNVs were evaluated as pathogenic. 
The diagnostic yield of 12% in targeted resequencing is consistent with the results of a 
previous study: Carvill et al. identified pathogenic variants in 10% of patients performing 
gene panel sequencing of 65 genes in 500 individuals with epileptic encephalopathies (Carvill 
et al. 2013a). However, the comparability of targeted resequencing studies is limited as 
findings depend on the genes, number of genes and phenotypes investigated. For example, 
Lemke et al. detected disease-causing variants in 16 (48%) of 33 individuals with various 
epilepsies sequencing 265 genes (Lemke et al. 2012). 
The frequency of pathogenic CNVs in array studies of individuals with epilepsy with or 
without comorbidities ranges from approximately 5% to 30% (Spreiz et al. 2014). The 
diagnostic yield of 11% in our CNV analysis lies within this range. Variation in diagnostic 
yields might be due to differences in array platforms, criteria of pathogenicity and 
investigated phenotypes. Besides in epilepsy, CNVs have also been established as an 
important source of mutation in ID, autism and CGA (Miller et al. 2010). Given the 
comorbidity of these disorders (Pellock 2004; Berg et al. 2011), the diagnostic yield of CNV 
studies in epilepsy might be upwardly biased due to overlapping phenotypes. Indeed, Mullen 
et al. identified significantly more individuals carrying rare recurrent CNVs in a cohort with 
GGE and ID (6/60; 10%) compared to a cohort with GGE alone (11/359; 3%) (Mullen et al. 
2013). Our study cohort included several individuals with ID, autism and CGA in addition to 
fever-associated epilepsy, with ID being the most frequent additional phenotype (table 3). 
However, in most of the patients with ID (18/26; 69%) cognitive impairment emerged in 
terms of an epileptic encephalopathy and development was unremarkable before seizure 
onset. Previous studies suggest that pathogenic CNVs are less frequent in patients with 
epileptic encephalopathies than in patients with GGE and ID (8/315; 2.5% vs. 11/60; 18%) 
(Mefford et al. 2011; Mullen et al. 2013). In addition, the frequency of pathogenic CNVs in 
epileptic encephalopathies does not exceed the one in GGE alone (8/315; 2.5% vs. up to 
46/517; 9% depending on criteria of pathogenicity) (Mefford et al. 2010; Mefford et al. 2011). 
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This indicates that ID linked to epileptic encephalopathies does not relevantly increase the 
amount of pathogenic CNVs. We compared patients with fever-associated epilepsy and ID 
present before epilepsy onset or with unknown starting point, autism or CGA to patients with 
fever-associated epilepsy without these additional features and did not find a significant 
difference in the amount of pathogenic CNVs (2/14 and 2/22, p=0.63, Fisher’s exact test). 
However, replication of our investigations in a larger cohort is needed to provide a more 
accurate estimate of diagnostic yields in fever-associated epilepsies with and without 
additional neurodevelopmental phenotypes. 
 
4.2 The impact of 19 candidate genes in recurrent FS and fever-associated 
epilepsies 
 
All pathogenic variants were identified in known epilepsy genes. In addition, we detected 13 
variants of unknown significance. Seven of these were found in five of 19 candidate genes. 
Variants of unknown significance were evaluated as such due to missense mutation type and 
unknown inheritance or missing segregation with the disorder. In several cases, pathogenicity 
scores pointed towards a benign variant.  
Our results do not give evidence of the investigated candidate genes having an impact in 
recurrent FS and fever-associated epilepsies. However, variants of unknown significance 
might still be disease-causing or contribute to the corresponding phenotype. All criteria of 
pathogenicity can only serve as guidelines, but not as general rules. For example, a variant 
might just seem to not segregate with the disorder due to reduced penetrance or phenocopies. 
The latter phenomenon is especially found with disorders having a high frequency in the 
general population as is the case for FS. In addition, several variants were of unknown 
significance due to the unavailability of parental DNA or family history, but might have 
occurred de novo or segregate with the disorder. 
In our study, we did not identify any pathogenic variants in 19 candidate epilepsy genes. The 
identification of new epilepsy genes remains difficult. Epilepsy is a genetically heterogeneous 
disorder and a certain gene might cause disease in only a small percentage of patients 
requiring large cohorts for gene identification. 
 
4.3 Extending the phenotypic spectrum of known epilepsy genes 
 
We identified eight pathogenic SCN1A mutations. This would usually not be surprising for a 
cohort with fever-associated epilepsies as SCN1A mutations are a known cause of Dravet 
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syndrome and FS+/GEFS+. However, five of eight patients previously had a negative 
mutation screening for SCN1A using Sanger sequencing. 
The phenomenon of SCN1A mutations in “SCN1A-negative” individuals has recently been 
discovered in different next generation sequencing projects (Suls et al. 2013a; Carvill et al. 
2014). An error in PCR resulting in the exclusive replication of the wildtype allele is a 
possible scenario leading to these false-negative findings. A bias towards one allele during 
PCR might occur through an impaired primer binding. If a patient carried a single nucleotide 
polymorphism (SNP) in the primer binding site of the mutated allele the primer might not be 
able to anneal. Only the wild type allele would be replicated and undergo sequencing. Errors 
might also occur during analysis of the electropherograms. Heterozygous mutations are 
sometimes missed by software algorithms and might also escape visual analysis. Capture and 
replication techniques preceding next generation sequencing are increasingly optimized in 
terms of allelic bias (Turner et al. 2009b) and as high-throughput sequencing produces many 
reads of the same sequence, mutations are less likely to escape analysis. 
The finding of missed SCN1A variants shows that SCN1A mutations can be detected in even 
more than the generally reported 70-80% in Dravet syndrome (Marini et al. 2011) and 10% in 
GEFS+ (Wallace et al. 2001b; Marini et al. 2007). Sanger sequencing might not be as 
sensitive as assumed and it might be worth retesting “SCN1A-negative” individuals with a 
next generation sequencing technique. 
 
We detected two additional pathogenic mutations in GABRA1 and SCN2A. The clinical 
presentation of the affected individuals has not yet been associated with mutations in these 
known epilepsy genes. 
A de novo GABRA1 mutation was identified in an individual showing a clinical picture of 
Dravet syndrome in the first years of life, but developing symptoms and signs of GGE over 
time. 
GABRA1 encodes the α1 subunit of the GABAA receptor that mediates inhibition of neuronal 
activity (Badawy et al. 2009). GABRA1 mutations have previously been described in two 
families with GGE and FS (Lachance-Touchette et al. 2011), a proband with sporadic CAE 
(Maljevic et al. 2006) and in autosomal dominant JME (Cossette et al. 2002). Our patient was 
also included in a study searching for genes that underlie SCN1A-negative Dravet syndrome 
(Carvill et al. 2014). In total, this study identified four GABRA1 mutations in 77 individuals 
with Dravet syndrome. A third study identified a de novo GABRA1 mutation in an individual 
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with infantile spasms out of 264 patients with infantile spasms and Lennox-Gastaut syndrome 
(Epi4K Consortium and Epilepsy Phenome/Genome Project 2013). 
Our work and the study by Carvill et al. extend the phenotypic spectrum of GABRA1 
mutations to Dravet syndrome. Mutations in the GABRA1 gene have a broad phenotypic 
spectrum with GGE and FS at the mild end up to severe epileptic encephalopathies as Dravet 
syndrome and infantile spasms. This phenotypic diversity might occur inter-, but also 
intraindividually as in our study patient who was first diagnosed with Dravet syndrome, but 
presented with GGE at a later point in development. 
 
We identified a de novo SCN2A mutation in a patient with a diagnosis of Dravet syndrome. 
However, considering the biphasic and disastrous seizure onset, FIRES was taken into 
account as a differential diagnosis. 
SCN2A encodes the α2 subunit of the neuronal sodium channel. Inherited SCN2A mutations 
have previously been identified in a patient with FS+ (Sugawara et al. 2001) and in families 
with benign familial neonatal-infantile seizures (BFNIS) (Heron et al. 2002). De novo 
mutations of SCN2A were implicated in early infantile epileptic encephalopathies including 
Dravet syndrome (Shi et al. 2012; Carvill et al. 2013a; Epi4K Consortium and Epilepsy 
Phenome/Genome Project 2013) and in autism spectrum disorders (Sanders et al. 2012). 
Our patient showed clinical features of Dravet syndrome and FIRES. Patients with FIRES 
have previously been investigated for mutations in SCN1A, POLG and PCDH19, but no 
pathogenic variants were found (Appenzeller et al. 2012). With our study patient, clinical 
features of FIRES have now been associated with a de novo SCN2A mutation. Sequencing of 





4.4 The importance of rare CNVs in fever-associated epilepsies 
 
We detected 13 rare CNVs in eight of 36 individuals with SCN1A-negative fever-associated 
epilepsies. We identified pathogenic CNVs in four and likely pathogenic CNVs in two 
patients. All pathogenic CNVs were known to occur in patients with different 
neurodevelopmental disorders and were hence not specific for fever-associated epilepsies. 
Our findings extend the phenotypic spectrum of several known microdeletion syndromes to 
fever-associated epilepsy. 
 
4.4.1 Discussion of pathogenic CNVs 
 
Pathogenic CNVs were discussed in Hartmann et al. 2015: 
 
We detected a pathogenic distal 1q21.1 duplication of unknown inheritance in a patient with 
SCN1A-negative Dravet syndrome. Autism, ID, dysmorphic features and macrocephaly have 
been described as the main phenotypes in duplication carriers. However, the high frequency 
of these clinical presentations might be due to an ascertainment bias as these features are 
common indications for array CGH testing. Several individuals with unspecified seizures and 
GGE have been reported in the literature (Brunetti-Pierri et al. 2008; Mefford et al. 2008; 
Rosenfeld et al. 2012). Our study patient did not have autism, dysmorphic features or 
macrocephaly, but presented with Dravet syndrome associated with ID. Our study adds 
features of Dravet syndrome to the phenoytpic spectrum of 1q21.1 duplications. 
 
A patient with recurrent febrile and afebrile GTCS, profound ID, autism and macrocephaly 
carried a distal 16p11.2 deletion. This recurrent CNV has previously been identified in 
individuals with developmental delay, behavioral problems, unusual facial morphology and 
obesity. Epileptic seizures have only rarely been described in 16p11.2 deletion carriers. Focal 
dyscognitive seizures occurred in an individual with abnormal configuration of both 
hippocampi (Barge-Schaapveld et al. 2011). In addition, recurrent febrile and afebrile seizures 
(Bachmann-Gagescu et al. 2010), SIGEI (Mefford et al. 2010) and unclassified epileptic 
encephalopathy with febrile and predominant absence seizures (Mefford et al. 2011) have 
been reported. Our study patient and previously described individuals with distal 16p11.2 
deletion presented with fever-associated epilepsy syndromes. Fever-associated epilepsy may 




The main phenotypes of individuals with 1q44 deletion comprise developmental delay, ID, 
microcephaly, short stature, corpus callosum anomalies (CCA) and seizures (Caliebe et al. 
2010; Ballif et al. 2012; Thierry et al. 2012). We identified a 1q44 deletion in a patient with 
all of these features besides microcephaly and CCA. In early infancy, the girl was diagnosed 
with Dravet syndrome as she presented with recurrent febrile GTCS and was suspected of 
having myoclonic seizures. However, throughout development, additional syndromic features 
were noted and the epilepsy showed a relatively benign course with seizure-free periods of 
several years. These findings were not in accordance with the diagnosis of Dravet syndrome 
and the patient’s seizure disorder was therefore reported as “unclassified fever-associated 
epilepsy”. 
Breakpoint mapping of the 1q44 deletion in our study patient indicated the disruption of the 
HNRNPU gene, suggesting HNRNPU as the causative gene. The identification of de novo and 
truncating mutations in patients with epileptic encephalopathies (Carvill et al. 2013a; Epi4K 
Consortium and Epilepsy Phenome/Genome Project 2013) suggested HNRNPU as the gene 
responsible for the epilepsy phenotype. Additional de novo HNRNPU mutations were 
identified in an individual with a complex phenotype including epilepsy, ID and CGA (Need 
et al. 2012) and a patient with epilepsy, ID and autism spectrum disorder (ASD) (Hamdan et 
al. 2014). 
Our findings and previously reported cases suggest that epilepsy may be a main phenotype of 
1q44 deletions spanning the HNRNPU gene. 
 
We also detected a 14q23.3 deletion disrupting GPHN in a patient with FS+. Homozygous 
mutations are a known cause of Molybdenum cofactor deficiency (Reiss et al. 2001; Reiss et 
al. 2011) as Gephyrin, the protein encoded by GPHN, is required for the biosynthesis of 
molybdenum cofactors (Stallmeyer et al. 1999). In addition, Gephyrin is essential for glycine 
and GABAA receptor clustering at postsynaptic sites (Feng et al. 1998; Kneussel et al. 1999). 
The involvement in synaptic accumulation of neurotransmitter receptors might be a link of 
GPHN to epilepsy. Hemizygous deletions have been identified in patients with autism, 
schizophrenia and GGE (Lionel et al. 2013; Dejanovic et al. 2014; Hu et al. 2015). Our 
patient presented with febrile and afebrile GTCS, supporting a causative role of hemizygous 
GPHN deletions in epilepsy and extending the associated phenotypic spectrum to mild fever-
associated epilepsies.  
Variable expressivity and reduced penetrance as observed in other pathogenic microdeletions 
may explain that our patient’s deletion was inherited from the unaffected mother. 
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4.4.2 Discussion of likely pathogenic CNVs 
 
Likely pathogenic CNVs were discussed in Hartmann et al. 2015: 
 
We identified a 1.6 Mb duplication of unknown inheritance at 3q13.11 in a patient with FS+ 
and borderline ID. This CNV included ALCAM, encoding a cell adhesion molecule, and 
CBLB, encoding a E3 ubiquitin ligase. ALCAM is increasingly expressed during 
neuroinflammation and mediates the recruitment of leukocytes across the blood-brain barrier 
(Cayrol et al. 2008). In addition, ALCAM is required for cell migration during chick 
diencephalic development (Heffron and Golden 2000). 
CBLB was described to promote T cell tolerance by negatively regulating T cell activation 
(Venuprasad 2010; Wallner et al. 2012). Cblb null mice show an enhancement of long-term 
memory retention (Tan et al. 2006) and another study suggested that proteins from the Cbl 
family suppress cell death in healthy neurons (Sproul et al. 2009). 
ALCAM and CBLB were the only genes included in a 2.5 Mb de novo deletion identified in a 
patient with multiple dysmorphic features and a congenital heart defect (Simovich et al. 
2008). However, ID and seizures as present in our study patient were not reported in this 
individual. 
ALCAM and CBLB were found to play a role in various processes in the brain. Both genes 
might contribute to our patient’s phenotype, but further studies are required to confirm their 
relevance in epilepsy. 
 
We detected two de novo duplications at 7p14.2 and 18q12.2 in a patient with SCN1A-
negative atypical Dravet syndrome. ELMO1, encoding a cytoplasmic protein promoting 
phagocytosis and cell migration (Gumienny et al. 2001), was the only gene partially included 
in the 7p14.2 duplication. The gene is highly expressed in brain (GNF Gene Expression Atlas 
2) (Su et al. 2004) and involved in dendritic spine morphogenesis in rat hippocampal neurons 
(Kim et al. 2011). Defective phagocytic clearance in Elmo1 null mice leads to accumulation 
of apoptotic nuclei resulting in impaired adult neurogenesis (Lu et al. 2011). 
Five zinc finger genes ZNF397, ZNF397OS, ZNF271, ZNF24 and ZNF396 were included in 
the 18q12.2 duplication. All genes code for transcription factors whose target genes and 
specific functions are largely unknown. The mouse homologue of ZNF24 was shown to have 
a vital role in early mouse development and cell proliferation (Li et al. 2006; Khalfallah et al. 
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2009) and Li et al. presumed that the transcription factor might be involved in brain 
development (Li et al. 2009b). 
Both duplications might contribute to our patient’s phenotype. Its high expression in the brain 
and relevance in neuronal morphogenesis make ELMO1 a promising candidate gene for 
epilepsy in this patient. 
 
In this study, duplications at 3q13.11, 7p14.2 and 18q12.2 were evaluated as likely pathogenic 
due to CNV size or de novo occurrence. The duplications comprized several genes that are 
involved in different brain processes and might have an impact on the epilepsy phenotype. 
However, the identified CNVs have not been associated with epilepsy so far and additional 
cases with overlapping CNVs or mutations in the discussed genes are needed to elucidate 





5 Summary and Conclusions 
 
Simple febrile seizures are frequent in the population and have a strong genetic contribution. 
However, genetic studies have not revealed any causative variants for simple febrile seizures 
yet, but have mainly been successful in fever-associated epilepsies like genetic epilepsy with 
febrile seizures plus and Dravet syndrome. Despite the discovery of several genes, most 
individuals with fever-associated epilepsies do not carry variants in these genes and further 
causative genetic variants need to be identified. Targeted resequencing and copy number 
variation analysis were successfully applied for the identification of pathogenic variants in 
different epilepsies including genetic generalized epilepsies and epileptic encephalopathies. In 
this study, we performed targeted resequencing and genome-wide array comparative genomic 
hybridization in patients with recurrent febrile seizures and fever-associated epilepsies. We 
aimed to evaluate the impact of 19 candidate epilepsy genes, define the phenotypic spectrum 
of 13 known epilepsy genes and to assess the importance of rare copy number variants in 
fever-associated epilepsies. 
 
We identified pathogenic single nucleotide variants in 10 (12%) of 84 patients with recurrent 
febrile seizures and fever-associated epilepsies. This cohort included 43 individuals with 
typical or atypical Dravet syndrome of which 35 previously tested negative for SCN1A 
sequence mutations. The diagnostic yield of targeted resequencing was consistent with a 
previous gene panel study. However, it has to be taken into account that mutation 
identification depends on the genes, number of genes and phenotypes studied. 
We detected pathogenic copy number variants in 4 (11%) of 36 SCN1A-negative individuals, 
as a subgroup of the first cohort. The diagnostic yield in our cohort was in accordance with 
previous array studies. Additional clinical features like intellectual disability, autism spectrum 
disorders and congenital anomalies might upwardly bias the diagnostic yield of copy number 
variant analysis in patients with epilepsy. Intellectual disability was the most frequent 
additional neurodevelopmental phenotype in our cohort. However, in most of our study 
patients, intellectual disability occurred in terms of an epileptic encephalopathy and previous 
studies suggest that intellectual disability linked to epileptic encephalopathies does not 
relevantly increase the amount of pathogenic copy number variants. 
 
Targeted resequencing did not identify any pathogenic mutations in candidate epilepsy genes. 
Seven rare variants in five of 19 candidate genes were classified as variants of unknown 
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significance. The investigation of larger cohorts might reveal pathogenic variants in some of 
the candidate genes. 
 
We extended the phenotypic spectrum of the known epilepsy genes GABRA1 and SCN2A. We 
identified a GABRA1 de novo mutation in a patient first diagnosed with Dravet syndrome, but 
with clinical features of genetic generalized epilepsy at a later point in development. Our 
finding supports GABRA1 as a new gene for patients with clinical features of Dravet 
syndrome in early childhood. We detected a de novo SCN2A mutation in a patient with 
features of Dravet syndrome and febrile infection-related epilepsy syndrome. While Dravet 
syndrome has already been associated with SCN2A mutations, our study suggests SCN2A as a 
new candidate gene for febrile infection-related epilepsy syndrome. 
SCN1A mutations were identified in patients previously tested negative for variants in this 
gene using Sanger sequencing. Next-generation sequencing techniques seem to be more 
sensitive in the identification of SCN1A mutations so that it might be worth retesting 
individuals that have been investigated with Sanger sequencing. 
 
All pathogenic copy number variants identified were not specific for fever-associated 
epilepsies, but extended the phenotypic spectrum of several known microdeletion syndromes 
to these epilepsies. Our study adds features of Dravet syndrome to the phenotypic 
presentations of 1q21.1 duplications. 16p11.2 deletion carriers may present with fever-
associated epilepsy as a recurring feature. In addition, our study and previous findings suggest 
epilepsy as a main phenotype of 1q44 deletions spanning the HNRNPU gene. Our results 
support a causative role of hemizygous GPHN deletions in epilepsy and extend the associated 
phenotypic spectrum to mild fever-associated epilepsies. 
 
Our study suggests that copy number variant analysis may be a useful step in the diagnostic 
work-up of fever-associated epilepsies with or without additional neurodevelopmental 
features once variants in major candidate genes such as SCN1A have been excluded. Targeted 
resequencing proved to be a powerful diagnostic tool in patients with fever-associated 
epilepsies solving 12% of cases and detecting SCN1A mutations in patients with previous 
negative Sanger sequencing for this gene. Our study identified pathogenic variants known to 
play a role in epilepsy and extended their phenotypic spectrum. Further efforts are required to 
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Reverse primer 1 CAAGCAGAAGACGGCATACGAGATTATCAGCGACACGCACGATCCGACGGTAGTGT 
Reverse primer 2 CAAGCAGAAGACGGCATACGAGATTGCGTGTAACACGCACGATCCGACGGTAGTGT 
Reverse primer 3 CAAGCAGAAGACGGCATACGAGATCGTTATCCACACGCACGATCCGACGGTAGTGT 
Reverse primer 4 CAAGCAGAAGACGGCATACGAGATTCAGATACACACGCACGATCCGACGGTAGTGT 
Reverse primer 5 CAAGCAGAAGACGGCATACGAGATTAGCCGATACACGCACGATCCGACGGTAGTGT 
Reverse primer 6 CAAGCAGAAGACGGCATACGAGATATCCGAATACACGCACGATCCGACGGTAGTGT 
Reverse primer 7 CAAGCAGAAGACGGCATACGAGATTGCTATGAACACGCACGATCCGACGGTAGTGT 
Reverse primer 8 CAAGCAGAAGACGGCATACGAGATGAACTACCACACGCACGATCCGACGGTAGTGT 
Reverse primer 9 CAAGCAGAAGACGGCATACGAGATGGTATTCGACACGCACGATCCGACGGTAGTGT 
Reverse primer 10 CAAGCAGAAGACGGCATACGAGATTACGAGTTACACGCACGATCCGACGGTAGTGT 
Reverse primer 11 CAAGCAGAAGACGGCATACGAGATGCACATAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 12 CAAGCAGAAGACGGCATACGAGATGAGCGATAACACGCACGATCCGACGGTAGTGT 
Reverse primer 13 CAAGCAGAAGACGGCATACGAGATACGTGTTAACACGCACGATCCGACGGTAGTGT 
Reverse primer 14 CAAGCAGAAGACGGCATACGAGATTATCCAGCACACGCACGATCCGACGGTAGTGT 
Reverse primer 15 CAAGCAGAAGACGGCATACGAGATTATCGGTTACACGCACGATCCGACGGTAGTGT 
Reverse primer 16 CAAGCAGAAGACGGCATACGAGATCTTGCGTAACACGCACGATCCGACGGTAGTGT 
Reverse primer 17 CAAGCAGAAGACGGCATACGAGATCTATTGTCACACGCACGATCCGACGGTAGTGT 
Reverse primer 18 CAAGCAGAAGACGGCATACGAGATTGCGATCTACACGCACGATCCGACGGTAGTGT 
Reverse primer 19 CAAGCAGAAGACGGCATACGAGATTGACGAAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 20 CAAGCAGAAGACGGCATACGAGATATTGGACGACACGCACGATCCGACGGTAGTGT 
Reverse primer 21 CAAGCAGAAGACGGCATACGAGATACATTGCCACACGCACGATCCGACGGTAGTGT 
Reverse primer 22 CAAGCAGAAGACGGCATACGAGATTCACTTGCACACGCACGATCCGACGGTAGTGT 
Reverse primer 23 CAAGCAGAAGACGGCATACGAGATTTACCGACACACGCACGATCCGACGGTAGTGT 
Reverse primer 24 CAAGCAGAAGACGGCATACGAGATCATGTACCACACGCACGATCCGACGGTAGTGT 
Reverse primer 25 CAAGCAGAAGACGGCATACGAGATTTGTTCCAACACGCACGATCCGACGGTAGTGT 
Reverse primer 26 CAAGCAGAAGACGGCATACGAGATTGATTATCACACGCACGATCCGACGGTAGTGT 
Reverse primer 27 CAAGCAGAAGACGGCATACGAGATCTCCTGATACACGCACGATCCGACGGTAGTGT 
Reverse primer 28 CAAGCAGAAGACGGCATACGAGATTCCTCTAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 29 CAAGCAGAAGACGGCATACGAGATGTACTCAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 30 CAAGCAGAAGACGGCATACGAGATCAATGAGGACACGCACGATCCGACGGTAGTGT 
Reverse primer 31 CAAGCAGAAGACGGCATACGAGATCACGCATAACACGCACGATCCGACGGTAGTGT 
Reverse primer 32 CAAGCAGAAGACGGCATACGAGATCAATAGCCACACGCACGATCCGACGGTAGTGT 
Reverse primer 33 CAAGCAGAAGACGGCATACGAGATCCTACAGAACACGCACGATCCGACGGTAGTGT 
Reverse primer 34 CAAGCAGAAGACGGCATACGAGATCACAGTAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 35 CAAGCAGAAGACGGCATACGAGATTAACGAGAACACGCACGATCCGACGGTAGTGT 
Reverse primer 36 CAAGCAGAAGACGGCATACGAGATTCTGCTTAACACGCACGATCCGACGGTAGTGT 
Reverse primer 37 CAAGCAGAAGACGGCATACGAGATTGTATAACACACGCACGATCCGACGGTAGTGT 
Reverse primer 38 CAAGCAGAAGACGGCATACGAGATGTATACATACACGCACGATCCGACGGTAGTGT 
Reverse primer 39 CAAGCAGAAGACGGCATACGAGATATGGCACAACACGCACGATCCGACGGTAGTGT 
Reverse primer 40 CAAGCAGAAGACGGCATACGAGATAACTCGAAACACGCACGATCCGACGGTAGTGT 
Reverse primer 41 CAAGCAGAAGACGGCATACGAGATGATCTGGTACACGCACGATCCGACGGTAGTGT 
Reverse primer 42 CAAGCAGAAGACGGCATACGAGATACAAGTCAACACGCACGATCCGACGGTAGTGT 
Reverse primer 43 CAAGCAGAAGACGGCATACGAGATACGAGACTACACGCACGATCCGACGGTAGTGT 
Reverse primer 44 CAAGCAGAAGACGGCATACGAGATATGAGTACACACGCACGATCCGACGGTAGTGT 
Reverse primer 45 CAAGCAGAAGACGGCATACGAGATATTCAAGCACACGCACGATCCGACGGTAGTGT 
Reverse primer 46 CAAGCAGAAGACGGCATACGAGATCGGAATTGACACGCACGATCCGACGGTAGTGT 
Reverse primer 47 CAAGCAGAAGACGGCATACGAGATCTGGAGTTACACGCACGATCCGACGGTAGTGT 
Reverse primer 48 CAAGCAGAAGACGGCATACGAGATGTCCATCAACACGCACGATCCGACGGTAGTGT 
Reverse primer 49 CAAGCAGAAGACGGCATACGAGATTAACAGTCACACGCACGATCCGACGGTAGTGT 
Reverse primer 50 CAAGCAGAAGACGGCATACGAGATCATTGTGCACACGCACGATCCGACGGTAGTGT 
Reverse primer 51 CAAGCAGAAGACGGCATACGAGATACTTGATTACACGCACGATCCGACGGTAGTGT 
Reverse primer 52 CAAGCAGAAGACGGCATACGAGATTTGACCGTACACGCACGATCCGACGGTAGTGT 
Reverse primer 53 CAAGCAGAAGACGGCATACGAGATACAATGTGACACGCACGATCCGACGGTAGTGT 
Reverse primer 54 CAAGCAGAAGACGGCATACGAGATAAGTTCCTACACGCACGATCCGACGGTAGTGT 
Reverse primer 55 CAAGCAGAAGACGGCATACGAGATCGCCATAAACACGCACGATCCGACGGTAGTGT 
Reverse primer 56 CAAGCAGAAGACGGCATACGAGATAGACGAGTACACGCACGATCCGACGGTAGTGT 
Reverse primer 57 CAAGCAGAAGACGGCATACGAGATACCGTATTACACGCACGATCCGACGGTAGTGT 
Reverse primer 58 CAAGCAGAAGACGGCATACGAGATGCTAACAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 59 CAAGCAGAAGACGGCATACGAGATCTATGCTGACACGCACGATCCGACGGTAGTGT 
Reverse primer 60 CAAGCAGAAGACGGCATACGAGATTCAACTCGACACGCACGATCCGACGGTAGTGT 
Table S2. Primers for RT-PCR and PCR of MIP capture products. 
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Primer name Primer sequence 
Reverse primer 61 CAAGCAGAAGACGGCATACGAGATTTCAAGAAACACGCACGATCCGACGGTAGTGT 
Reverse primer 62 CAAGCAGAAGACGGCATACGAGATACGGTGTAACACGCACGATCCGACGGTAGTGT 
Reverse primer 63 CAAGCAGAAGACGGCATACGAGATACCAGTATACACGCACGATCCGACGGTAGTGT 
Reverse primer 64 CAAGCAGAAGACGGCATACGAGATCCATGTACACACGCACGATCCGACGGTAGTGT 
Reverse primer 65 CAAGCAGAAGACGGCATACGAGATTACGCAATACACGCACGATCCGACGGTAGTGT 
Reverse primer 66 CAAGCAGAAGACGGCATACGAGATTCTATAGTACACGCACGATCCGACGGTAGTGT 
Reverse primer 67 CAAGCAGAAGACGGCATACGAGATTTCAGAGTACACGCACGATCCGACGGTAGTGT 
Reverse primer 68 CAAGCAGAAGACGGCATACGAGATATCCTGTCACACGCACGATCCGACGGTAGTGT 
Reverse primer 69 CAAGCAGAAGACGGCATACGAGATTTCCACGTACACGCACGATCCGACGGTAGTGT 
Reverse primer 70 CAAGCAGAAGACGGCATACGAGATTAACTTAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 71 CAAGCAGAAGACGGCATACGAGATATCTTAGAACACGCACGATCCGACGGTAGTGT 
Reverse primer 72 CAAGCAGAAGACGGCATACGAGATCATACCTGACACGCACGATCCGACGGTAGTGT 
Reverse primer 73 CAAGCAGAAGACGGCATACGAGATTAGAGTCTACACGCACGATCCGACGGTAGTGT 
Reverse primer 74 CAAGCAGAAGACGGCATACGAGATATGACCAAACACGCACGATCCGACGGTAGTGT 
Reverse primer 75 CAAGCAGAAGACGGCATACGAGATTATACGGTACACGCACGATCCGACGGTAGTGT 
Reverse primer 76 CAAGCAGAAGACGGCATACGAGATCGTTCTATACACGCACGATCCGACGGTAGTGT 
Reverse primer 77 CAAGCAGAAGACGGCATACGAGATGGAATAGCACACGCACGATCCGACGGTAGTGT 
Reverse primer 78 CAAGCAGAAGACGGCATACGAGATTCAGACCAACACGCACGATCCGACGGTAGTGT 
Reverse primer 79 CAAGCAGAAGACGGCATACGAGATCCTCGTAAACACGCACGATCCGACGGTAGTGT 
Reverse primer 80 CAAGCAGAAGACGGCATACGAGATCATTCGGAACACGCACGATCCGACGGTAGTGT 
Reverse primer 81 CAAGCAGAAGACGGCATACGAGATACGGCAATACACGCACGATCCGACGGTAGTGT 
Reverse primer 82 CAAGCAGAAGACGGCATACGAGATTAACCATGACACGCACGATCCGACGGTAGTGT 
Reverse primer 83 CAAGCAGAAGACGGCATACGAGATTTGTCAACACACGCACGATCCGACGGTAGTGT 
Reverse primer 84 CAAGCAGAAGACGGCATACGAGATCAGTTGAAACACGCACGATCCGACGGTAGTGT 
Reverse primer 85 CAAGCAGAAGACGGCATACGAGATAGAAGCTAACACGCACGATCCGACGGTAGTGT 
Reverse primer 86 CAAGCAGAAGACGGCATACGAGATTGCATCCTACACGCACGATCCGACGGTAGTGT 
Reverse primer 87 CAAGCAGAAGACGGCATACGAGATACTGGAGAACACGCACGATCCGACGGTAGTGT 
Reverse primer 88 CAAGCAGAAGACGGCATACGAGATCCATAGTTACACGCACGATCCGACGGTAGTGT 
Reverse primer 89 CAAGCAGAAGACGGCATACGAGATCTAAGTTAACACGCACGATCCGACGGTAGTGT 
Reverse primer 90 CAAGCAGAAGACGGCATACGAGATGTTAGCCTACACGCACGATCCGACGGTAGTGT 
Reverse primer 91 CAAGCAGAAGACGGCATACGAGATTTCGTGAGACACGCACGATCCGACGGTAGTGT 
Reverse primer 92 CAAGCAGAAGACGGCATACGAGATAGTCTCTTACACGCACGATCCGACGGTAGTGT 
Reverse primer 93 CAAGCAGAAGACGGCATACGAGATGGATATACACACGCACGATCCGACGGTAGTGT 
Reverse primer 94 CAAGCAGAAGACGGCATACGAGATAAGACGCTACACGCACGATCCGACGGTAGTGT 
Reverse primer 95 CAAGCAGAAGACGGCATACGAGATGTGTCTGAACACGCACGATCCGACGGTAGTGT 
Reverse primer 96 CAAGCAGAAGACGGCATACGAGATAGAGTGCAACACGCACGATCCGACGGTAGTGT 
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Primer name Primer sequence 
Forward primer CATACGAGATCCGTAATCGGGAAGCTGAAG 
Reverse primer ACACGCACGATCCGACGGTAGTGT 
Barcode primer ACACTACCGTCGGATCGTGCGTGT 




Patient Mutation Forward primer Reverse primer 
Patient A 
 
GABRA1, chr5:161322732A>C (hg19), c.917A>C 




SCN1A, chr2:166870327C>T (hg19), c.3632G>A 




SCN1A, chr2:166870299A>C (hg19), c.3660T>G 




SCN1A, chr2:166848659G>T (hg19), c.5126C>A 




SCN1A, chr2:166904174A>G (hg19), c.1133T>C 









SCN1A, chr2:166904178G>A (hg19), c.1129C>T 




SCN1A, chr2:166848852G>A (hg19), c.4933C>T 




SCN1A, chr2:166872228C>A (hg19), c.3439G>T 




SCN2A, chr2:166223873G>C (hg19), c.3776G>C 




GABRG2, chr5:161580306C>T (hg19), c.1480C>T 









SLC2A1, chr1:43394886C>T (hg19), c.967G>A 
(NM_006516), p.Val323Met (NP_006507) 
CCGCATCCCTCACTCTCCAG GCAGTGTCCCTTCTGCCTGA 




Patient Mutation Forward primer Reverse primer 
Patient N 
 
SLC2A1, chr1:43394653C>T (hg19), c.1024G>A 




SPTAN1, chr9:131395569G>A (hg19), c.7390G>A 




SPTAN1, chr9:131367651G>A (hg19), c.3941G>A 




ADAM22, chr7:87778355T>C (hg19), c.1549T>C 




ADAM22, chr7:87760671C>G (hg19), c.913C>G 




ADAM23, chr2:207460812C>T (hg19), c.2285C>T 









DLGAP2, chr8:1514057A>T (hg19), c.1199A>T 




DLGAP2, chr8:1616750G>C (hg19), c.1826G>C 




EPHA6, chr3:96945251A>G (hg19), c.1258A>G 
(NM_001080448), p.Met420Val (NP_001073917) 
ACACTGTACTCTGAGATCCAATGT TGTAGGGCCTCAAACCAGTG 








sequence, start, end 
(Build 36) 
Reverse primer: 


























Table S5. Deletion breakpoint mapping: Primer pairs and length of PCR fragments. 
a 
as 
estimated from gel electrophoresis; (table as published in Hartmann et al 2015, license agreement with 
John Wiley and Sons available) 
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